var title_f26_46_27360="MRI Spinal cord infarct";
var content_f26_46_27360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI findings in spinal cord ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance images of the thoracolumbar spine demonstrating spinal cord infarction in a patient with paraplegia after thoracoabdominal aneurysm repair. T2 weighted sagittal imaging through the center of the spinal cord (left panel) showed central infarction extending from the high thoracic level into the lumbar segments. T2 weighted axial images of the spinal cord at the thoracic level demonstrated central infraction (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael L McGarvy, MD and Michael Mullen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27360=[""].join("\n");
var outline_f26_46_27360=null;
var title_f26_46_27361="Nail matrix punch biopsy";
var content_f26_46_27361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Punch biopsy of the nail matrix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of Informa Healthcare, from An Atlas of Diseases of the Nail, Rich P, Scher RK, New York, 2003; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27361=[""].join("\n");
var outline_f26_46_27361=null;
var title_f26_46_27362="Latex allergy - allergic contact dermatitis";
var content_f26_46_27362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis due to latex allergy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An individual was visiting a family member in the hospital who was on isolation. She forgot that she had an allergy to latex and donned latex gloves. She developed local erythema and pruritus (no urticaria), followed by vesicles, which ruptured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27362=[""].join("\n");
var outline_f26_46_27362=null;
var title_f26_46_27363="Algorithm for choosing the optimal cardiac stress test";
var content_f26_46_27363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Algorithm for choosing the optimal cardiac stress test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 654px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG: electrocardiogram; LBBB: left bundle branch block; LVH: left ventricular hypertrophy; PET: positron emission tomography; SPECT: single photon emission computed tomography; V: ventricular.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27363=[""].join("\n");
var outline_f26_46_27363=null;
var title_f26_46_27364="Ferumoxytol: Drug information";
var content_f26_46_27364=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferumoxytol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/32/35331?source=see_link\">",
"    see \"Ferumoxytol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7890587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feraheme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14329048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Feraheme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7897720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7897833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses expressed in mg of",
"     <b>",
"      elemental",
"     </b>",
"     iron.",
"     <b>",
"      Note:",
"     </b>",
"     Test dose: Product labeling does not indicate need for a test dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Iron-deficiency anemia in chronic kidney disease:",
"     </b>",
"     I.V.: 510 mg (17 mL) as a single dose, followed by a second 510 mg dose 3-8 days (U.S. labeling) or 2-8 days (Canadian labeling) after initial dose. Assess response at least 30 days following the second dose. U.S. manufacturer labeling states the recommended dose may be readministered in patients with persistent or recurrent iron-deficiency anemia.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7897834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7898123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14330242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7897839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feraheme&reg;: Elemental iron 30 mg/mL (17 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7897718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7897835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intravenously as an undiluted injection at a rate &le;1 mL/second (30 mg of elemental iron/second). Do not administer if solution has particulate matter or is discolored (solution is black to reddish-brown).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis patients should receive injection after at least 1 hour of hemodialysis has been completed and once blood pressure has stabilized.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7897722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of iron-deficiency anemia in chronic kidney disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7897717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ferumoxytol may be confused with ferric gluconate, iron dextran complex, iron sucrose",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7897767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (&le;3%), edema (2%), peripheral edema (2%), chest pain (1%), hypertension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (3%), headache (2%), fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (1%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (4%), nausea (3%), constipation (2%), vomiting (2%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (1%), muscle spasms (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (1%), dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions (&le;4%; serious reactions: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic/anaphylactoid reactions, angioedema, cardiac/cardiorespiratory arrest, cardiac rhythm abnormalities, congestive heart failure, cyanosis, fatigue, hypotension (clinically significant); infusion site reactions (including bruising, burning, erythema, irritation, pain, swelling, warmth); ischemic myocardial events, loss of consciousness, pulse absent, syncope, tachycardia, unresponsiveness, urticaria, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7897763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ferumoxytol or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Evidence of iron overload; anemia not caused by iron deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7897764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Serious hypersensitivity reactions, including rare anaphylactic and anaphylactoid reactions, may occur, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness; equipment for resuscitation and trained personnel experienced in handling emergencies should be immediately available during use. Monitor patients for signs/symptoms of hypersensitivity reactions for &ge;30 minutes and until clinically stable following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: Hypotension, including serious hypotensive reactions, may occur; monitor patients for hypotension following administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Do not administer in the presence of tissue iron overload; periodic monitoring of hemoglobin, serum ferritin, serum iron, and transferrin saturation is recommended. Serum iron and transferrin-bound iron may be overestimated in laboratory assays if level is drawn during the first 24 hours following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Magnetic resonance (MR) imaging: Administration may alter MR imaging; conduct anticipated MRI studies prior to use. MR imaging alterations may persist for &le;3 months following use, with peak alterations anticipated in the first 2 days following administration. If MR imaging is required within 3 months after administration, use T1- or proton density-weighted MR pulse sequences to decrease effect on imaging. Do not use T2-weighted sequence MR imaging prior to 4 weeks following ferumoxytol administration.  Ferumoxytol does not interfere with X-ray, computed tomography (CT), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound or nuclear medicine imaging.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7907577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7897723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7897724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal malformations and decreased fetal weights were observed in animal studies at maternally toxic doses. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only if potential benefit justifies potential risk to fetus. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron-deficiency anemia in pregnancy. Treatment of iron-deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7897726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7897727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron-fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Feraheme Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     510 mg/17 mL (17 mL): $520.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7897837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, serum ferritin, serum iron, transferrin saturation (for at least 1 month following second injection and periodically); signs/symptoms of hypotension following administration; signs/symptoms of hypersensitivity reactions (&ge;30 minutes following administration)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F7897809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemoglobin: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: 13.5-16.5 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: 12.0-15.0 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum iron: 40-160 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Total iron-binding capacity: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7897807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Superparamagnetic iron oxide coated with a low molecular weight semisynthetic carbohydrate; iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow where the iron is released from the complex. The released iron is either transported into storage pools or is transported via plasma transferrin for incorporation into hemoglobin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7897810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.16 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Iron released from iron-carbohydrate complex after uptake in the reticuloendothelial system macrophages of the liver, spleen, and bone marrow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis: Ferumoxytol is not removed by hemodialysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27364/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Auerbach M, &ldquo;Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No&rdquo;,",
"      <i>",
"       Am J of Kidney Dis",
"      </i>",
"      , 2008, 52(5):826-9 [editorial].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27364/abstract-text/18971010/pubmed\" id=\"18971010\" target=\"_blank\">",
"        18971010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27364/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-3):1-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27364/abstract-text/9563847/pubmed\" id=\"9563847\" target=\"_blank\">",
"        9563847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(23):2848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27364/abstract-text/8133626/pubmed\" id=\"8133626\" target=\"_blank\">",
"        8133626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh A, Patel T, Hertel J, et al, &ldquo;Safety of Ferumoxytol in Patients With Anemia and CKD&rdquo;,",
"      <i>",
"       Am J of Kidney Dis",
"      </i>",
"      , 2008, 52(5):907-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27364/abstract-text/18824288/pubmed\" id=\"18824288\" target=\"_blank\">",
"        18824288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9044 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27364=[""].join("\n");
var outline_f26_46_27364=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7890587\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14329048\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897720\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897833\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897834\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7898123\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14330242\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897839\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897718\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897835\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897722\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897717\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897767\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897763\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897764\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299328\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7907577\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897723\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897724\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897726\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897727\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322355\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897837\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897809\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897807\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897810\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/32/35331?source=related_link\">",
"      Ferumoxytol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_46_27365="Flucytosine: Pediatric drug information";
var content_f26_46_27365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flucytosine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"    see \"Flucytosine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/22/15717?source=see_link\">",
"    see \"Flucytosine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ancobon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Administer in combination with amphotericin B to prevent development of resistance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Susceptible infection:",
"     </b>",
"     Initial: 25-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Candidal meningitis",
"     </b>",
"     : 75-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     used in combination with amphotericin B to prevent development of resistance was used in five premature neonates (GA: &gt;24 weeks, PMA at treatment: &gt;26 weeks) for 3-20 days of therapy in a report summary of one NICU's 10-year experience (Fernandez, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"      see \"Flucytosine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Administer in combination with amphotericin B due to development of resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Candidiasis, invasive (including CNS disease); treatment (HIV-exposed/-positive):",
"     </b>",
"     25-37.5 mg/kg/dose every 6 hours (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cryptococcal disease, disseminated (including CNS disease); treatment (HIV-exposed/-positive):",
"     </b>",
"     25 mg/kg/dose every 6 hours (CDC, 2009a; Perfect, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents:",
"     <b>",
"      Cryptococcal meningitis; treatment (HIV-exposed/-positive):",
"     </b>",
"     25 mg/kg/dose every 6 hours (duration: 2 weeks) or fluconazole (duration: 4-6 weeks) (CDC, 2009a; Perfect, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      General dosing:",
"     </b>",
"     12.5-37.5 mg/kg/dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Monitor serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 25-37.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 25-37.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 25-37.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis or peritoneal dialysis: 25-37.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CRRT: 25-37.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Manufacturer&rsquo;s labeling: Use lower initial dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ancobon&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food over a 15-minute period to decrease incidence and severity of nausea and vomiting",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In combination with amphotericin B in the treatment of serious Candidal or Cryptococcal pulmonary or urinary tract infections, sepsis, meningitis, or endocarditis (resistance emerges if flucytosine is used as a single agent); used in combination with another antifungal agent for treatment of chromomycosis and aspergillosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flucytosine may be confused with fluorouracil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ancobon&reg; may be confused with Oncovin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F171826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, myocardial toxicity, ventricular dysfunction, chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, fatigue, hallucinations, headache, parkinsonism, psychosis, pyrexia, sedation, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, photosensitivity, pruritus, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, duodenal ulcer, enterocolitis, hemorrhage, nausea, ulcerative colitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, bone marrow aplasia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Acute hepatic injury, bilirubin increased, hepatic dysfunction, jaundice, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, BUN increased, crystalluria, renal failure, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flucytosine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid monotherapy due to rapid emergence of resistance.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5936967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with renal impairment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; renal impairment may lead to accumulation; dosage modification required in patients with impaired renal function based on serum flucytosine concentrations; use with extreme caution in patients with bone marrow suppression, patients with AIDS, patients being treated with radiation or with drugs which depress bone marrow; closely monitor hematologic, renal, and hepatic function of all patients receiving flucytosine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; bone marrow toxicity can be irreversible and is potentially fatal; hepatotoxicity and bone marrow toxicity appear to be dose related; monitor concentrations closely and adjust dose accordingly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cytarabine (Conventional): May diminish the therapeutic effect of Flucytosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1047423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the rate, but not the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Flucytosine is metabolized to fluorouracil which may cause adverse events if administered during pregnancy; refer to the fluorouracil monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, creatinine, BUN, alkaline phosphatase, AST, ALT, CBC, platelet count; serum flucytosine concentrations;",
"     <i>",
"      in vitro",
"     </i>",
"     susceptibility tests to flucytosine",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1047414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic concentration: 25-100 mcg/mL; with invasive candidiasis, maintain peak plasma concentration between 40-60 mcg/mL; increased bone marrow suppression with sustained serum flucytosine concentration &gt;100 mcg/mL; obtain flucytosine concentration 60-120 minutes after an oral dose; obtain trough concentration immediately before the next dose; maintain trough &ge;25 mcg/mL to prevent emergence of resistant strains",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penetrates fungal cells and is converted to fluorouracil by cytosine deaminase which competes with uracil interfering with fungal RNA and protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid; rate of absorption is delayed in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed into body tissues and fluids including CSF, aqueous humor, peritoneal fluid, bronchial secretions, liver, spleen, kidney, heart, and joints",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.68 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 2.9% to 4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal hepatic metabolism; deaminated to 5-fluorouracil (probably by gut bacteria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 78% to 89%; decreased in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 4-34 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 7.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-6 hours (prolonged as high as 200 hours in anuria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2.5 &plusmn; 1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 75% to 90% excreted unchanged in urine by glomerular filtration; small portion is excreted in the feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/22/15717?source=see_link\">",
"      see \"Flucytosine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resistance develops rapidly if used alone; more rapid emergence of fungal resistance may occur when lower doses are used",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F171767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral suspension may be made with capsules and distilled water. Empty the contents of ten 500 mg capsules in a mortar; add small portions of distilled water and mix to a uniform paste. Mix while adding distilled water in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     500 mL; transfer to a 500 mL volumetric flask, rinse mortar several times with distilled water, and add sufficient quantity of distilled water to make 500 mL. Store in glass or plastic prescription bottles and label \"shake well\". Stable for 70 days refrigerated and 14 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Wintermeyer SM and Nahata MC, &ldquo;Stability of Flucytosine in an Extemporaneously Compounded Oral Liquid,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(4):407-9.",
"     <span class=\"pubmed-id\">",
"      8673661",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baley JE, Meyers C, Kliegman RM, et al, &ldquo;Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(5):791-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27365/abstract-text/2329429 /pubmed\" id=\"2329429 \" target=\"_blank\">",
"        2329429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27365/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27365/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez M, Moylett EH, Noyola DE, et al, \"Candidal Meningitis in Neonates: A 10-Year Review,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 31(2):458-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27365/abstract-text/10987705/pubmed\" id=\"10987705\" target=\"_blank\">",
"        10987705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hope WW, Warn PA, Sharp A, et al, \"Optimization of the Dosage of Flucytosine in Combination With Amphotericin B for Disseminated Candidiasis: A Pharmacodynamic Rationale for Reduced Dosing,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2007, 51(10):3760-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, \"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27365/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soltani M, Tobin CM, Bowker KE, et al, \"Evidence of Excessive Concentrations of 5-Flucytosine in Children Aged Below 12 Years: A 12-Year Review of Serum Concentrations From a UK Clinical Assay Reference Laboratory,\"",
"      <i>",
"       Int J Antimicrob Agents",
"      </i>",
"      , 2006, 28(6):574-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27365/abstract-text/17085019/pubmed\" id=\"17085019\" target=\"_blank\">",
"        17085019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13304 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27365=[""].join("\n");
var outline_f26_46_27365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708774\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171786\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047411\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442535\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047403\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171744\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047416\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047407\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047415\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171826\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047420\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047402\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5936967\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299342\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171753\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047423\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047410\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047414\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047401\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047419\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047409\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047421\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171767\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=related_link\">",
"      Flucytosine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/22/15717?source=related_link\">",
"      Flucytosine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_46_27366="Dienogest: Drug information";
var content_f26_46_27366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dienogest: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/43/693?source=see_link\">",
"    see \"Dienogest: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13450885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Visanne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13450887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13451029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"     Oral: 2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13451031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13451030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in manufacturer's labeling; dienogest undergoes hepatic metabolism and therefore systemic exposure may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use in patients with a history of or current severe hepatic disease is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13451042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Visanne&reg;: 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13451041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13451035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals. If a dose is not absorbed due to vomiting and/or diarrhea within 3-4 hours of administration, repeat dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13450888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of pelvic pain associated with endometriosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13450884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Visanne&reg; may be confused with Vyvanse&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13450963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (7%), depression (3%), sleep disturbance (2%), irritability (1%), migraine (1%), nervousness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Acne (2%), alopecia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Breast discomfort (5%), ovarian cyst (3%), libido decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (4%), weight gain (4%), abdominal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Vaginal bleeding (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%, postmarketing, and/or case reports: Abdominal discomfort, anemia, anxiety, appetite increased, attention disturbance, autonomic nervous system imbalance, back pain, bone pain, breast induration, breast mass, circulatory disorder (nonspecified), constipation, dermatitis, diarrhea, dry eye, dry skin, edema, extremity pain, fibrocystic breast disease, flatulence, genital discharge, GI inflammation, glucose intolerance, heaviness in extremities, hot flashes, mood changes, muscle spasm, onychoclasis, palpitations, pelvic pain, photosensitivity, pigmentation disorder, pruritus, tinnitus, UTI, vaginal candidiasis, vomiting, vulvovaginal dryness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13450892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dienogest or any component of the formulation; undiagnosed abnormal vaginal bleeding; active venous thromboembolic disorder; history of or current arterial and cardiovascular disease (eg, MI, CVA); diabetes mellitus with vascular involvement; history of or current severe hepatic disease where liver function tests remain abnormal; history of or current hepatic neoplasia (benign or malignant); known or suspected sex-hormone-dependent malignancy; ocular lesions due to ophthalmic vascular disease, such as partial or complete vision loss or defect in visual fields; current or history of migraine with focal aura; breast-feeding; known or suspected pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13450893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding: Use is associated with irregular menstrual bleeding (eg, amenorrhea, infrequent or frequent bleeding, prolonged bleeding) and may be aggravated in some women (eg, those with fibroids). Bleeding patterns generally show a reduced intensity over time. If bleeding irregularities continue with prolonged use, appropriate diagnostic measures should be taken to rule out endometrial pathology (eg, endometrial sampling, pelvic ultrasound). Consider discontinuation of therapy with prolonged heavy bleeding. Pretreatment menstrual bleeding patterns return within 2 months of therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in the frequency of breast cancer; however,  studies are not consistent. Data is insufficient to determine if progestin only contraceptives also increase this risk. Routine breast examinations are recommended during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chloasma: May occur occasionally; women with a history of chloasma should avoid sun or ultraviolet radiation exposure during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cholestatic jaundice: Patients with a prior history of cholestatic jaundice during pregnancy or due to the use of sex steroids should discontinue use of dienogest if cholestatic jaundice reoccurs during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic tumors: Rare cases of benign and malignant hepatic tumors have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ovarian cysts: Persistent ovarian cysts which are often asymptomatic may occur during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pruritus: Patients with a prior history of pruritus during pregnancy or due to use of sex steroids should discontinue dienogest therapy if pruritus reoccurs during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Retinal vascular lesions: Progestin use has been associated with retinal vascular lesions; discontinue pending examination in case of sudden vision loss, complete loss of vision, sudden onset of proptosis, diplopia, or migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Venous thromboembolism (VTE): Progestin-only therapy has been associated with a slight but non-significant increase risk of VTE in some studies; discontinue therapy promptly with suspicion or symptoms of a thrombotic event. Discontinue use in patients with prolonged immobilization and at least 4 weeks prior to elective surgery; may resume therapy 2 weeks after complete remobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Depression: Use with caution in patients with depression; discontinue use with onset of clinically relevant depression or with aggravation of pre-existing depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic disease: Use is contraindicated in patients with a history of or current severe hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: The risk of stroke may be increased in women with hypertension.  Discontinue if clinically significant hypertension develops during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Osteoporosis: Weigh risk-benefit in patients at risk of osteoporosis prior to initiating therapy; use is associated with a moderate decrease in endogenous estrogen levels; in a small study, a reduction in mean bone mineral density was not observed 6 months after initiating therapy though long term data are not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Not indicated for use in the geriatric population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Smokers: The risk of cardiovascular side effects is increased in women who smoke cigarettes.  Women should be advised not to smoke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not intended for use as a contraceptive.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10327802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Dienogest. Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13450977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may induce dienogest hepatic metabolism and decrease its systemic exposure.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13450889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal studies, teratogenic effects were not observed; however, use of high dose dienogest during late pregnancy impaired fertility of female offspring. Based on limited data, inadvertent exposure in pregnancy has not shown adverse effects to the fetus, however use in known or suspected pregnancy is contraindicated. Rule out pregnancy prior to initiating therapy. Use of hormonal contraceptives is not recommended during dienogest therapy. Nonhormonal contraceptives should be employed during treatment. Ovulation is often inhibited during therapy although normal menstruation usually returns within 2 months of therapy discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13450890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13450891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether dienogest is excreted into human breast milk. The risk of thromboembolism may be increased immediately postpartum.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13451039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy test prior to initiating therapy; routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram; adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding; bone mineral density (prior to therapy in patients at risk for osteoporosis); signs and symptoms of thromboembolic disorders, vision changes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      VisaBelle (IL);",
"     </li>",
"     <li>",
"      Visanne (AR, AT, AU, CH, CO, CZ, DE, DK, FI, FR, HN, NL, NO, PT, SE, SG);",
"     </li>",
"     <li>",
"      Visannette (EE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13450980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dienogest is a steroid with antiandrogen properties that lacks androgen, mineralcorticoid or glucocorticoid activity. Exhibits strong progestogenic effects although it binds uterine progesterone receptors with an affinity much lower (about one-tenth) than that of progesterone. Decreases estradiol production and thus suppresses estradiol&rsquo;s trophic effects on eutopic and ectopic endometrium. Inhibits cellular proliferation via direct antiproliferative, immunologic, and antiangiogenic effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13451013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid and almost complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 40 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~90% nonspecifically to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~9-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (minimal amount as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Strowitzki T, Faustmann T, Gerlinger C, et al, &ldquo;Dienogest in the Treatment of Endometriosis-Associated Pelvic Pain: A 12-week, Randomized, Double-Blind, Placebo-Controlled Study,\"",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2010, 151(2):193-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27366/abstract-text/20444534/pubmed\" id=\"20444534\" target=\"_blank\">",
"        20444534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strowitzki T, Marr J, Gerlinger C, et al, &ldquo;Dienogest is as Effective as Leuprolide Acetate in Treating the Painful Symptoms of Endometriosis: A 24-Week, Randomized, Multicentre, Open-Label Trial,\"",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2010, 151(2):193-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/46/27366/abstract-text/20444534/pubmed\" id=\"20444534\" target=\"_blank\">",
"        20444534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17068 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27366=[""].join("\n");
var outline_f26_46_27366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450885\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451029\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451031\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451030\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451042\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451041\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451035\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450888\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450884\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450963\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450892\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450893\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299188\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327802\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450977\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450889\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450890\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450891\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451039\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992817\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450980\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451013\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17068|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/43/693?source=related_link\">",
"      Dienogest: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_46_27367="Rash - Henoch Schonlein purpura IgA vasculitis A";
var content_f26_46_27367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63367%7EPEDS%2F72094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63367%7EPEDS%2F72094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the classic skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis), with clusters of typical ecchymoses, petechiae, and palpable lesions on the legs in a typical distribution (gravity/pressure-dependent areas).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Kim, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Kim, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27367=[""].join("\n");
var outline_f26_46_27367=null;
var title_f26_46_27368="Rifampin and isoniazid: Drug information";
var content_f26_46_27368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifampin and isoniazid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/13/27861?source=see_link\">",
"    see \"Rifampin and isoniazid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      IsonaRif&trade;;",
"     </li>",
"     <li>",
"      Rifamate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rifamate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     Oral: 2 capsules/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     IsonaRif&trade;: Rifampin 300 mg and isoniazid 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rifamate&reg;: Rifampin 300 mg and isoniazid 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of active tuberculosis; see individual agents for additional information",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rifamate&reg; may be confused with rifampin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5207604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Isoniazid may enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Rifamycin Derivatives may increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Rifamycin Derivatives may increase the metabolism of Angiotensin II Receptor Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Candesartan; Eprosartan; Olmesartan; Telmisartan; Valsartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Rifampin may increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): Rifamycin Derivatives may increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dolasetron; Granisetron; Palonosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Rifamycin Derivatives may increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Rifampin may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Rifamycin Derivatives may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Isoniazid may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Rifamycin Derivatives may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Rifampin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Rifampin may decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination).  Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Rifamycin Derivatives may decrease the serum concentration of BusPIRone.  Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Rifamycin Derivatives may increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Rifampin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Isoniazid may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Rifampin may decrease the serum concentration of Caspofungin.  Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Rifampin may increase the metabolism of Chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorzoxazone: Isoniazid may decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Rifamycin Derivatives may enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Rifampin may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Rifamycin Derivatives may increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: CYP2E1 Inhibitors (Moderate) may decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Rifamycin Derivatives may increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Rifampin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Rifampin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May decrease the metabolism of Rifamycin Derivatives. Rifamycin Derivatives may increase the metabolism of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Rifamycin Derivatives may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Rifampin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: Rifampin may decrease the serum concentration of Efavirenz.  Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Rifampin may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Rifampin may increase the metabolism of Erlotinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: Rifampin may decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethionamide: May increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Rifamycin Derivatives may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Rifamycin Derivatives may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Rifampin may decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Rifampin may decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Rifampin may decrease the serum concentration of Fosaprepitant. More specifically, rifampin may decrease concentrations of the active metabolite aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Isoniazid may increase the serum concentration of Fosphenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Rifamycin Derivatives may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Rifamycin Derivatives may increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Rifampin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Isoniazid may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Isoniazid may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Rifampin may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Rifampin may increase serum concentrations of the active metabolite(s) of Leflunomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Rifampin may enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Lopinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Rifamycin Derivatives may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Rifampin may decrease the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Morphine (Systemic): Rifamycin Derivatives may decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Rifampin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Rifampin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: Rifampin may decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OxyCODONE: Rifampin may decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Isoniazid may increase the serum concentration of Phenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Rifamycin Derivatives may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: Rifampin may diminish the antiplatelet effect of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Rifamycin Derivatives may decrease the serum concentration of Propafenone.  Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrazinamide: May enhance the hepatotoxic effect of Rifampin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Rifampin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Rifampin may decrease the serum concentration of Raltegravir.  Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Rifamycin Derivatives may increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Rifampin may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Rifamycin Derivatives may increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Rifampin may decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: Rifampin may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast.  The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Rifampin may enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. Rifampin may decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Rifampin may increase the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Rifampin may increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Rifamycin Derivatives may increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Rifampin may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): Rifampin may decrease the serum concentration of Terbinafine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Isoniazid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Rifampin may decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Rifampin may decrease the serum concentration of Tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Rifampin may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Rifamycin Derivatives may increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Rifamycin Derivatives may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Rifamycin Derivatives may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Rifampin monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Rifamate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-300 mg (60): $338.57",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bifix (PH);",
"     </li>",
"     <li>",
"      Dipicin-INH (PH);",
"     </li>",
"     <li>",
"      R-Cinex 600 (IN);",
"     </li>",
"     <li>",
"      Ramicin-ISO (ID, PH);",
"     </li>",
"     <li>",
"      Refinah 300 (MY, TH);",
"     </li>",
"     <li>",
"      Rifaina (TW);",
"     </li>",
"     <li>",
"      Rifamazid (PL);",
"     </li>",
"     <li>",
"      Rifazida (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Rifinah (AE, AR, BF, BH, BJ, CI, CY, DE, EG, ET, FR, GB, GH, GM, GN, GR, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NZ, OM, PK, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Rifinah 300 (MY, TW);",
"     </li>",
"     <li>",
"      Rifoldin 300MG + INH (AT);",
"     </li>",
"     <li>",
"      Rifzin (PH);",
"     </li>",
"     <li>",
"      Rimactazid (BB, BF, BJ, BM, BS, BZ, CH, CI, ET, GH, GM, GN, GR, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PE, PR, SC, SD, SE, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Rimactazid 300 (PH);",
"     </li>",
"     <li>",
"      Rimpazid 450 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10077 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-126470AF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27368=[""].join("\n");
var outline_f26_46_27368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218270\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218271\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218280\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218272\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218273\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218261\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218252\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218263\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218284\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5207604\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218278\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218258\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218267\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218275\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218266\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218268\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218265\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/13/27861?source=related_link\">",
"      Rifampin and isoniazid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_46_27369="Outpatient treatment of community-acquired pneumonia in children";
var content_f26_46_27369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outpatient treatment of community-acquired pneumonia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/46/27369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27369/contributors\">",
"     William J Barson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/46/27369/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27369/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27369/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/46/27369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27369/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/46/27369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia. CAP is a common and potentially serious illness with considerable morbidity.",
"   </p>",
"   <p>",
"    The Pediatric Infectious Diseases",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America and the British Thoracic Society have developed clinical practice guidelines for the evaluation and treatment of CAP in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outpatient treatment of CAP in infants and children will be reviewed here. Neonatal pneumonia and inpatient treatment of pneumonia are discussed separately, as are the epidemiology, etiology, clinical features, and diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link\">",
"     \"Inpatient treatment of pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to hospitalize a child with community-acquired pneumonia (CAP) is individualized based upon age, underlying medical problems, and clinical factors including severity of illness (",
"    <a class=\"graphic graphic_table graphicRef72015 \" href=\"UTD.htm?28/35/29244\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Hospitalization generally is warranted for infants younger than three to six months of age, unless a viral etiology or",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    is suspected and they are normoxemic and relatively asymptomatic. Hospitalization is also warranted for a child of any age whose family cannot provide appropriate care and assure compliance with the therapeutic regimen. Additional indications for hospitalization include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemia (oxygen saturation &lt;90 percent in room air at sea level)",
"     </li>",
"     <li>",
"      Dehydration, or inability to maintain hydration orally; inability to feed in an infant",
"     </li>",
"     <li>",
"      Moderate to severe respiratory distress: Respiratory rate &gt;70 breaths per minute for infants &lt;12 months of age and &gt;50 breaths per minute for older children; retractions; nasal flaring; difficulty breathing; apnea; grunting",
"     </li>",
"     <li>",
"      Toxic appearance (more common in bacterial pneumonia and may suggest a more severe course) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Underlying conditions that may predispose to a more serious course of pneumonia (eg, cardiopulmonary disease, genetic syndromes, neurocognitive disorders), may be worsened by pneumonia, even viral pneumonia (eg, metabolic disorder) or may adversely affect response to treatment (eg, immunocompromised host)",
"     </li>",
"     <li>",
"      Complications (eg,",
"      <span class=\"nowrap\">",
"       effusion/empyema)",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"       \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"       \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suspicion or confirmation that CAP is due to a pathogen with increased virulence, such",
"      <em>",
"       as Staphylococcus aureus",
"      </em>",
"      or group A",
"      <em>",
"       streptococcus",
"      </em>",
"     </li>",
"     <li>",
"      Failure of outpatient therapy (worsening or no response in 48 to 72 hours) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment failure'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with community acquired pneumonia (CAP) who are treated in the outpatient setting typically are treated empirically; tests to identify a microbiologic etiology are not recommended for most children who are well enough to be treated in the outpatient setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Decisions regarding empiric therapy are complicated by the substantial overlap in the clinical presentation of bacterial and nonbacterial pneumonias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. Treatment decisions are usually based upon algorithms that include patient age (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ), epidemiologic and clinical information, and diagnostic laboratory and imaging studies (if such studies were obtained) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/4\">",
"     4",
"    </a>",
"    ]. Consultation with a specialist in infectious disease may be helpful in children with medication allergies or comorbid conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'Etiologic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few randomized controlled trials to guide the choice of empiric antibiotics in children with CAP. Factors that must be considered include the spectrum of likely pathogens, antimicrobial susceptibility, simplicity, tolerability, palatability, safety, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/7\">",
"     7",
"    </a>",
"    ]. The recommendations of most guidelines are based upon observations regarding the susceptibility of the most likely pathogen or pathogens, rather than on evidence of the superiority of one antibiotic over another [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The clinical response to the most commonly used antimicrobials appears to be similar, regardless of etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The response within the first 48 to 72 hours of empiric therapy (or lack of therapy if viral etiology is most likely) helps to determine whether additional evaluation or changes in therapy are necessary. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Monitoring response'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Children &lt;5 years",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of neonatal pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     One to six months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants younger than three to six months of age with suspected bacterial CAP or who are hypoxemic (oxygen saturation &lt;90 percent in room air at sea level) should be admitted to the hospital for empiric therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In afebrile infants one to four months of age with CAP, the most likely bacterial pathogen is",
"    <em>",
"     C. trachomatis",
"    </em>",
"    (ie, \"afebrile pneumonia of infancy\") [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Infants who are thought to have afebrile pneumonia of infancy can be treated in the outpatient setting if they are not hypoxemic and remain afebrile [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link&amp;anchor=H17#H17\">",
"     \"Chlamydia trachomatis infections in the newborn\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     Bordetella pertussis",
"    </em>",
"    is a less common, but more severe, cause of pneumonia in young infants; fever may or may not be present. Like",
"    <em>",
"     C. trachomatis",
"    </em>",
"    ,",
"    <em>",
"     B. pertussis",
"    </em>",
"    is susceptible to the macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/4\">",
"     4",
"    </a>",
"    ]. However, young infants who are thought to have",
"    <em>",
"     B. pertussis",
"    </em>",
"    -associated pneumonia should be admitted to the hospital because they are at risk for complications (eg, hypoxia, apnea, pulmonary hypertension, etc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Hospitalization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Six months to five years",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34408226\">",
"    <span class=\"h4\">",
"     Viral pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral etiologies predominate during early childhood, and apparent viral pneumonia (ie, gradual onset, preceding upper airway symptoms, diffuse findings on auscultation, lack of toxic appearance) should",
"    <strong>",
"     not",
"    </strong>",
"    be treated with antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clues to etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'Etiologic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No effective antivirals are available for most viral pneumonias, with the exception of influenza. Initiation of antiviral treatment for influenza (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ) as soon as possible is recommended for children at high risk for complications of influenza pneumonia (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 3",
"    </a>",
"    ); laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and young children with known or suspected chronic disease (eg, bronchopulmonary disease, neuromuscular disease, etc) are at increased risk for severe or complicated viral lower respiratory tract infection (LRTI). If such children are not admitted to the hospital, they merit close monitoring in the outpatient setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34408249\">",
"    <span class=\"h4\">",
"     Bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    is the most frequent cause of \"typical\" bacterial pneumonia in children of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bacterial pneumonia in preschool children usually causes more severe infection, with abrupt onset and moderate to severe respiratory distress, which may require inpatient therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for hospitalization'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children younger than five years who are thought to have bacterial CAP based upon clinical presentation, examination findings, and supportive radiographic or laboratory data if obtained (eg, lobar consolidation on radiograph, white blood cell count [WBC]",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL,",
"    </span>",
"    C-reactive protein &gt;35 to 60",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [3.5 to 6",
"    <span class=\"nowrap\">",
"     mg/dL]),",
"    </span>",
"    but do not require inpatient therapy,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    is usually considered the drug of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. We suggest high dose amoxicillin (90 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into two or three doses; maximum dose 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    is preferred because it is effective against the majority of bacterial pathogens for CAP in this age group, is well tolerated, and is inexpensive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The higher dose of amoxicillin is suggested because of the increasing prevalence of antibiotic-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    isolated from patients with community-acquired respiratory tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Amoxicillin is more active in vitro than any of the oral cephalosporins against these isolates. Universal infant immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) resulted in a decreased prevalence of penicillin resistant pneumococci. However, it was associated with the emergence of antibiotic-resistant invasive serotypes, some of which are included in the 13-valent pneumococcal conjugate vaccine (PCV13) (eg, serotype 19A) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1\">",
"     1",
"    </a>",
"    ]. The effects of PCV13 on antibiotic resistance have yet to be determined; pending that information, we continue to suggest high-dose rather than standard dose amoxicillin (ie, 40 to 45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) when amoxicillin is used to treat CAP in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are prospective, comparative data supporting the efficacy of twice daily dosing of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    for the treatment of acute otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], similar data are not available for documented pneumococcal pneumonia in children. Unless the etiologic agent is identified as a",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    isolate with a minimum inhibitory concentration (MIC) of &lt;2",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    dividing the total daily 90 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose of amoxicillin into three doses may be warranted. Twice daily dosing for pneumonia due to a",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    isolate with an MIC of 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is predicted to achieve a clinical and microbiologic cure in only 65 percent of children, whereas the same total daily dose divided in three equal portions is predicted to achieve a cure in 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children with non-type 1 hypersensitivity reactions to penicillin (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 4",
"    </a>",
"    ), second or third generation cephalosporins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    ) is an acceptable alternative to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1\">",
"     1",
"    </a>",
"    ]. For children with type 1 hypersensitivity reactions (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 4",
"    </a>",
"    ) to penicillin,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or a macrolide may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, if local resistance rates are high for clindamycin and macrolides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     levofloxacin",
"    </a>",
"    may be preferable. Doses are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the infant or child who is suspected to have bacterial CAP and is unable to tolerate liquids at the time of presentation, a single initial dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50 to 75",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    may be administered intramuscularly or intravenously before starting oral antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264608206\">",
"    <span class=\"h4\">",
"     Atypical pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Mycoplasma pneumoniae",
"    </em>",
"    and",
"    <em>",
"     Chlamydophila pneumoniae",
"    </em>",
"    are less common than",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    in children younger than five years with CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/5\">",
"     5",
"    </a>",
"    ]. However, they can occur in this age group and should be considered in children without a pneumonia-associated complication who fail to improve after 48 to 72 hours of empiric therapy for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ), at which time a macrolide could be added or substituted (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Children &ge;5 years",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289604\">",
"    <span class=\"h3\">",
"     Typical and atypical bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    is the most frequent cause of \"typical\" bacterial pneumonia in children of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, in otherwise healthy children five years and older with CAP who are not ill enough to require hospitalization,",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    are the most likely pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/4,10,19\">",
"     4,10,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest macrolide antibiotics for initial empiric therapy for CAP in children older than five years who are treated as outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. However, the prevalence of macrolide-resistant",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    is increasing in some geographic regions, including Asia, Europe, Israel, and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/20-27\">",
"     20-27",
"    </a>",
"    ]. The reported prevalence of resistance among",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    isolates ranges from approximately 10 percent in the US to 90 percent in China [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    is an alternative for children &gt;6 months and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    for children &gt;8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1\">",
"     1",
"    </a>",
"    ]. The British Thoracic Society clinical practice guideline suggests",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    as the first-line therapy for children of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/2\">",
"     2",
"    </a>",
"    ]. Doses are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among the macrolide antibiotics,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    have a more convenient dosing schedule and fewer side effects than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    , but erythromycin is less expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/8,28,29\">",
"     8,28,29",
"    </a>",
"    ]. Macrolide antibiotics may provide coverage for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , which is the most frequent typical bacterial pathogen for all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. However, approximately 50 percent of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    isolates are resistant to macrolides. Failure to respond to macrolide therapy may indicate the development of a complication, a macrolide-resistant pathogen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the need to alter therapy to provide better pneumococcal coverage. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the significant resistance of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    to macrolides, fluoroquinolones (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) are another reasonable alternative for the outpatient treatment of CAP in skeletally mature patients. In addition to their excellent gram-negative spectrum, the fluoroquinolones are active against a number of the pathogens responsible for CAP, including beta-lactam-susceptible and non-susceptible",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    , and",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/33\">",
"     33",
"    </a>",
"    ]. However,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    resistant to levofloxacin has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289597\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of antiviral treatment for influenza (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ) as soon as possible is recommended for children at high risk for complications of influenza pneumonia (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 3",
"    </a>",
"    ); laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aspiration pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired aspiration pneumonia is usually treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    .",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is an alternative for patients allergic to penicillin. Doses are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In neurologically compromised skeletally mature adolescents who may be prone to aspiration events, empiric treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg once per day) is an alternative. Moxifloxacin is active against anaerobic bacteria, as well as the usual treatable causes of CAP:",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    , and",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled trials have been performed to determine the appropriate duration of antimicrobial therapy in radiographically confirmed childhood pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/2\">",
"     2",
"    </a>",
"    ]. Current practice in the developed world determines the duration of therapy based upon the age of the host, likely causative agent, and severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that infants &ge;4 months and children with uncomplicated pneumonia suspected or confirmed to be caused by routine pathogens (ie,",
"      <em>",
"       S. pneumonia",
"      </em>",
"      ,",
"      <em>",
"       M. pneumonia",
"      </em>",
"      ,",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      ) be treated for 7 to 10 days; the course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      is five days [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,8\">",
"       1,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The duration of treatment for",
"      <em>",
"       C. trachomatis",
"      </em>",
"      pneumonia in young infants is discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link&amp;anchor=H17#H17\">",
"       \"Chlamydia trachomatis infections in the newborn\", section on 'Treatment'",
"      </a>",
"      ) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis found three days of oral antimicrobial therapy to be as effective as five days for nonsevere community-acquired pneumonia in children aged 2 to 59 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the studies included in the meta-analysis were performed in developing countries, where it is not feasible to perform radiographs or evaluation for microbiologic etiology; pneumonia was diagnosed by the World Health Organization (WHO) criteria, which are based on clinical findings and respiratory rate thresholds. In another study, only 14 percent of children diagnosed with nonsevere pneumonia by the WHO criteria had radiographic evidence of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/36\">",
"     36",
"    </a>",
"    ]. Many of the children in the meta-analysis probably had viral pneumonia, for which antibiotic therapy is not warranted. This is supported by a subsequent randomized trial in which the clinical outcomes did not differ for children aged 2 to 59 months who were diagnosed with nonsevere pneumonia by the WHO criteria and treated for three days with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitoring response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CAP who are treated as outpatients (including those who were not initially treated with antibiotics) should have follow-up within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Follow-up may be performed by phone. Children with CAP who are appropriately treated generally show signs of improvement within 48 to 72 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who do not improve as anticipated, the following possibilities must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2,12,38\">",
"     1,2,12,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative or coincident diagnoses (eg, foreign body aspiration) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H33#H33\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Development of complications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2294532#H2294532\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Complications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ineffective antibiotic coverage (lack of coverage for the actual etiology or resistant organism)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264608675\">",
"    <span class=\"h4\">",
"     Worsened condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose condition has worsened require additional evaluation and hospitalization. They also should undergo radiologic evaluation to look for the development of complications. Laboratory tests should be performed to try to establish a microbiologic diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Laboratory evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H2#H2\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Hospitalization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264608611\">",
"    <span class=\"h4\">",
"     Failure to improve",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who fail to improve, but have not worsened, it may be reasonable to add or strengthen coverage for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    or atypical bacteria if these organisms were not covered in the initial therapy (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. It is also important to consider underlying or comorbid conditions (eg, immunodeficiency, anatomic abnormality). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to improve while being treated with a beta-lactam antibiotic (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or cephalosporin) may indicate infection caused by penicillin-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    or",
"    <em>",
"     S. aureus",
"    </em>",
"    (either methicillin-susceptible or -resistant) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/39\">",
"     39",
"    </a>",
"    ]. If penicillin-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    is suspected, a change in antibiotic therapy to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    may be indicated.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    is an option if there is a high rate of pneumococcal resistance to clindamycin. Doses are provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ). If",
"    <em>",
"     S. aureus",
"    </em>",
"    is suspected, the child should be hospitalized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link\">",
"     \"Inpatient treatment of pneumonia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to improve while being treated with a macrolide antibiotic may indicate the need to alter therapy to provide better coverage for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    or macrolide-resistant",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    . For patients initially treated with macrolides, better pneumococcal coverage can be achieved by the addition of high-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , a cephalosporin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ), or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Among these options, we prefer high-dose amoxicillin because it is well tolerated and inexpensive. Amoxicillin and cephalosporins may provide coverage for other potential, albeit less common causes, of bacterial pneumonia in older children (eg,",
"    <em>",
"     Haemophilus influenza",
"    </em>",
"    type b, nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    ,",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    , group A",
"    <em>",
"     streptococcus",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/10\">",
"     10",
"    </a>",
"    ]. Clindamycin provides coverage for",
"    <em>",
"     S. aureus",
"    </em>",
"    . For children who have type 1 hypersensitivity (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 4",
"    </a>",
"    ) to penicillins, a fluoroquinolone (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) may be used. Tetracyclines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) and fluoroquinolones can be used if macrolide-resistant",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/40\">",
"     40",
"    </a>",
"    ]. Doses are provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H21#H21\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The families of children who are managed as outpatients should be instructed regarding management of fever and pain, maintaining adequate hydration, and identification of deterioration (eg, persistent fever, increased retractions, use of accessory muscles, grunting, inability to feed) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with pneumonia usually have fever and may have pleuritic chest pain, which can lead to shallow breathing and impaired ability to cough [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/2\">",
"       2",
"      </a>",
"      ]. Administration of antipyretics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      analgesics can be used to keep the child comfortable. Adequate pain control may promote coughing, which facilitates airway clearance. Antitussives should be avoided as none have been found to be effective in pneumonia. Symptomatic treatment of cough is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H15315058#H15315058\">",
"       \"The common cold in children: Treatment and prevention\", section on 'Cough'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants and young children with respiratory distress may be better able to maintain hydration if fluids are provided in small volumes more frequently than in large volumes less often.",
"     </li>",
"     <li>",
"      Gentle suction of the nares may be helpful in infants and children whose nares are blocked by nasal secretions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are appropriately treated for community-acquired pneumonia (CAP) gradually improve with time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/41\">",
"     41",
"    </a>",
"    ]. Cough after pertussis commonly persists for many weeks and up to four months after infection. The symptoms associated with viral lower respiratory tract infections, particularly cough, usually resolve in less than one month in healthy infants and children, but may rarely last for up to three to four months. Cough may persist for as long as three to four months after viral pneumonia or pertussis. Children who are recovering from typical or atypical bacterial pneumonia may continue to cough for several weeks and have moderate dyspnea on exertion for two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up radiographs are not necessary in asymptomatic children with uncomplicated CAP. Follow-up radiographs two to three weeks after completion of therapy may be helpful in assessing alternate diagnoses or coincident conditions in children with recurrent pneumonia, persistent symptoms, severe atelectasis, unusually located infiltrates, or round pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/1,2,42\">",
"     1,2,42",
"    </a>",
"    ]. Conditions that must be considered if a round pneumonia fails to resolve on follow-up imaging include congenital lung sequestration, metastatic Wilms tumor, cavitary necrosis, pleural pseudocyst, and primary lung carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have evaluated the utility of follow-up radiographs in cohorts of children with acute radiologically proven CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. Three of the studies included clinical as well as radiologic follow-up at three to seven weeks after initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. In each of these studies, follow-up radiographs were normal or improved in asymptomatic children. Residual findings, even when present, did not result in additional therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most otherwise healthy children who develop pneumonia recover without any long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/32\">",
"     32",
"    </a>",
"    ]. Although some data suggest that nearly one-half of children who are hospitalized for viral pneumonia have symptoms of asthma five years after hospitalization, it is not clear whether this is related to unrecognized asthma at the time of presentation with pneumonia or a tendency to develop asthma after viral community-acquired pneumonia (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27369/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"       \"Patient information: Pneumonia in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community. The clinical manifestations and diagnosis of CAP are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision to hospitalize a child with pneumonia must be individualized and is based upon age, underlying medical problems, and severity of illness (",
"      <a class=\"graphic graphic_table graphicRef72015 \" href=\"UTD.htm?28/35/29244\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with CAP who are treated in the outpatient setting are treated empirically. It is not necessary to identify a microbiologic etiology in children who are well enough to be treated as outpatients. Decisions regarding empiric antimicrobial therapy for CAP in children are usually based upon age unless there are other overriding epidemiologic or clinical factors to suggest a specific etiologic agent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants younger than three to six months of age with suspected bacterial CAP or who are hypoxemic should be admitted to the hospital for management. Afebrile infants one to four months of age who are thought to have afebrile pneumonia of infancy (eg,",
"      <em>",
"       Chlamydia trachomatis",
"      </em>",
"      ) can be treated in the outpatient setting if they are not hypoxemic and remain afebrile. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link\">",
"       \"Inpatient treatment of pneumonia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link\">",
"       \"Chlamydia trachomatis infections in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that empiric antibiotic therapy for CAP in children six months to five years of age who are thought to have bacterial pneumonia (eg, abrupt onset, moderate to severe respiratory distress, and supportive laboratory data if obtained) include coverage for",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      (",
"      <a class=\"graphic graphic_table graphicRef80561 \" href=\"UTD.htm?18/23/18814\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Children &lt;5 years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that empiric antibiotic therapy for CAP in children &ge;5 years include coverage for atypical bacteria (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Children &ge;5 years'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants and children six months and older, the usual duration of antimicrobial therapy is five days for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      and 7 to 10 days for other agents. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are treated for CAP as outpatients should have follow-up within 24 to 48 hours. Those whose condition has worsened at follow-up should be evaluated for potential complications and hospitalized. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring response'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link\">",
"       \"Inpatient treatment of pneumonia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children recovering from CAP may continue to cough for several weeks to four months, depending upon the etiology. Those recovering from typical or atypical bacterial pneumonia may have moderate dyspnea on exertion for two to three months. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up radiographs in children with uncomplicated CAP who remain asymptomatic are not needed. Follow-up radiographs two to three weeks after completion of therapy may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, unusually located infiltrates, or round pneumonia. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most otherwise healthy children who develop pneumonia recover without any long-term sequelae. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/1\">",
"      Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/2\">",
"      Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/3\">",
"      Russell G. Community acquired pneumonia. Arch Dis Child 2001; 85:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/4\">",
"      McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/5\">",
"      Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/6\">",
"      Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax 2002; 57:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/7\">",
"      Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) 2004; 43:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/8\">",
"      Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/9\">",
"      Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/10\">",
"      Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156:S703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/11\">",
"      Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 46:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/12\">",
"      Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/13\">",
"      Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/14\">",
"      Behre U, Burow HM, Quinn P, et al. Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children. Infection 1997; 25:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/15\">",
"      Principi N, Marchisio P, Bigalli L, Massironi E. Amoxicillin twice daily in the treatment of acute otitis media in infants and children. Eur J Pediatr 1986; 145:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/16\">",
"      Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J 2010; 29:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/17\">",
"      Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/18\">",
"      Chumpa A, Bachur RG, Harper MB. Bacteremia-associated pneumococcal pneumonia and the benefit of initial parenteral antimicrobial therapy. Pediatr Infect Dis J 1999; 18:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/19\">",
"      Hammerschlag MR. Atypical pneumonias in children. Adv Pediatr Infect Dis 1995; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/20\">",
"      Peuchant O, M&eacute;nard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/21\">",
"      Averbuch D, Hidalgo-Grass C, Moses AE, et al. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011; 17:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/22\">",
"      Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/23\">",
"      Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012; 17:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/24\">",
"      Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011; 66:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/25\">",
"      Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis 2010; 67:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/26\">",
"      Miyashita N, Kawai Y, Akaike H, et al. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect Dis 2012; 12:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Mycoplasma pneumoniae respiratory illness - two rural counties, West Virginia, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/28\">",
"      Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/29\">",
"      Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993; 103:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/30\">",
"      Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) 2005; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/31\">",
"      Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/32\">",
"      Sandora TJ, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/33\">",
"      Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 2007; 26:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/34\">",
"      Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/35\">",
"      Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev 2008; :CD005976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/36\">",
"      Hazir T, Nisar YB, Qazi SA, et al. Chest radiography in children aged 2-59 months diagnosed with non-severe pneumonia as defined by World Health Organization: descriptive multicentre study in Pakistan. BMJ 2006; 333:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/37\">",
"      Hazir T, Nisar YB, Abbasi S, et al. Comparison of oral amoxicillin with placebo for the treatment of world health organization-defined nonsevere pneumonia in children aged 2-59 months: a multicenter, double-blind, randomized, placebo-controlled trial in pakistan. Clin Infect Dis 2011; 52:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/38\">",
"      Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med 2004; 98:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/39\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/40\">",
"      B&eacute;b&eacute;ar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011; 6:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/41\">",
"      Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/42\">",
"      Griscom NT. Pneumonia in children and some of its variants. Radiology 1988; 167:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/43\">",
"      McLennan MK. Radiology rounds. Round pneumonia. Can Fam Physician 1998; 44:751, 757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/44\">",
"      Kim YW, Donnelly LF. Round pneumonia: imaging findings in a large series of children. Pediatr Radiol 2007; 37:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/45\">",
"      Eggli KD, Newman B. Nodules, masses, and pseudomasses in the pediatric lung. Radiol Clin North Am 1993; 31:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/46\">",
"      Rose RW, Ward BH. Spherical pneumonias in children simulating pulmonary and mediastinal masses. Radiology 1973; 106:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/47\">",
"      Grossman LK, Wald ER, Nair P, Papiez J. Roentgenographic follow-up of acute pneumonia in children. Pediatrics 1979; 63:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/48\">",
"      Virkki R, Juven T, Mertsola J, Ruuskanen O. Radiographic follow-up of pneumonia in children. Pediatr Pulmonol 2005; 40:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/49\">",
"      Gibson NA, Hollman AS, Paton JY. Value of radiological follow up of childhood pneumonia. BMJ 1993; 307:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/50\">",
"      Heaton P, Arthur K. The utility of chest radiography in the follow-up of pneumonia. N Z Med J 1998; 111:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/51\">",
"      Wacogne I, Negrine RJ. Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia? Arch Dis Child 2003; 88:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/52\">",
"      Sur&eacute;n P, Try K, Eriksson J, et al. Radiographic follow-up of community-acquired pneumonia in children. Acta Paediatr 2008; 97:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27369/abstract/53\">",
"      Clark CE, Coote JM, Silver DA, Halpin DM. Asthma after childhood pneumonia: six year follow up study. BMJ 2000; 320:1514.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5987 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27369=[""].join("\n");
var outline_f26_46_27369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Children &lt;5 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - One to six months",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Six months to five years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34408226\">",
"      Viral pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34408249\">",
"      Bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H264608206\">",
"      Atypical pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Children &ge;5 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H289604\">",
"      - Typical and atypical bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H289597\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aspiration pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitoring response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H264608675\">",
"      Worsened condition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H264608611\">",
"      Failure to improve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/35/29244\" title=\"table 1\">",
"      Severity of pneumonia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/23/18814\" title=\"table 2\">",
"      Empiric oral rx pneumonia child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/50/33579\" title=\"table 3\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 4\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=related_link\">",
"      Management and prognosis of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=related_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_46_27370="Histopathology of placental disorders";
var content_f26_46_27370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Histopathology of placental disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Drucilla J Roberts, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/46/27370/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/46/27370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathological examination of the placenta is probably the most underutilized pathologic assessment of any human tissue. The placenta provides a wealth of information, retrospectively about the fetus and prospectively regarding the infant. Its examination is an essential component of the autopsy in cases of fetal or infant death, often gives useful insights for the diagnosis and treatment of sick newborns, and reflects the impact of maternal disorders on pregnancy. The following examples illustrate how placental examination aids in a number of difficult situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Legal issues regarding the presence of acute versus chronic perinatal stresses and insults",
"     </li>",
"     <li>",
"      Diagnosis of specific etiologies of abnormal pregnancies",
"     </li>",
"     <li>",
"      Diagnosis of zygosity in multifetal gestation",
"     </li>",
"     <li>",
"      Improved management of subsequent pregnancies",
"     </li>",
"     <li>",
"      Assessment of newborn risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Placental disorders and histopathology will be discussed here. The normal anatomy and gross examination of the placenta are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=see_link\">",
"     \"Gross examination of the placenta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UMBILICAL CORD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic findings in the cord can be grouped as congenital remnants, infections, meconium, and masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Congenital remnants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The end of the umbilical cord closest to the infant often contains residual developmental structures such as the allantoic and vitelline ducts and vitelline vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/1\">",
"     1",
"    </a>",
"    ]. None of these findings has clinical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common intrauterine infection is bacterial (\"acute\") chorioamnionitis, which is an amniotic fluid infection caused by",
"    <span class=\"nowrap\">",
"     cervical/vaginal",
"    </span>",
"    flora breaching the amniotic cavity. The inflammatory response to this infection can be of both maternal and fetal origin. As an example, the umbilical cord may harbor maternal inflammatory cells (primarily neutrophils) that have infiltrated from the decidua to the amniotic fluid. Alternatively, the fetus may respond to infectious stimuli with a fetal inflammatory neutrophilic response in which fetal inflammatory cells migrate from fetal vessels (including those of the umbilical cord) toward the infectious agent in the cord, membranes, or amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Umbilical cord inflammation has many names, such as funisitis and vasculitis. Standardization of terminology has been proposed to clarify the source (maternal or fetal) of the inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/3\">",
"     3",
"    </a>",
"    ] due to a significant difference in the risk for development of neurologic compromise in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/4\">",
"     4",
"    </a>",
"    ]. Funisitis involving only the external surface of the cord and Wharton's jelly most likely originated from outside the fetus and is maternal in origin. The inflammatory cells seen migrating through the fetal vessels in the cord are evidence of a fetal response and are diagnostic of systemic fetal inflammatory response syndrome (",
"    <a class=\"graphic graphic_picture graphicRef74438 \" href=\"UTD.htm?7/33/7704\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/5\">",
"     5",
"    </a>",
"    ]. Funisitis is predictive of a lower median Bayley psychomotor developmental index, 94 versus 99 among infants without funisitis (OR 1.3, 95% CI 1.1-1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/6\">",
"     6",
"    </a>",
"    ]. It may also be a risk factor for other adverse outcomes as inflammation of the umbilical cord may be a marker for vascular inflammation elsewhere in the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21929?source=see_link\">",
"     \"Placental pathology in cases of neurologically impaired infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The umbilical cord is trophic for some specific infectious organisms including candida (",
"    <a class=\"graphic graphic_picture graphicRef53199 \" href=\"UTD.htm?13/18/13604\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/5\">",
"     5",
"    </a>",
"    ] and toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/5\">",
"     5",
"    </a>",
"    ]. These organisms can also be observed in the areas of inflammation. Candidal infection is frequently associated with neutrophilic microabscesses on the external surface of the umbilical cord. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Meconium stained cord",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meconium pigment in the amniotic fluid will be picked up by macrophages in the placental membranes and umbilical cord and change the color and clarity of these structures. However, this is an uncommon finding compared to the frequency of meconium in amniotic fluid, suggesting that heavy or long duration of exposure to meconium is required to stain the membranes.",
"   </p>",
"   <p>",
"    A high concentration of meconium present for more than 12 hours can damage the umbilical cord by causing apoptosis of smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/7\">",
"     7",
"    </a>",
"    ]. The histologic findings are an orangeophilic (ie, orange appearing cytoplasm) apoptotic-like degeneration of the arteries (usually) in a characteristic pattern that spares the centrally facing myocytes. An inflammatory infiltrate is often present (",
"    <a class=\"graphic graphic_picture graphicRef67487 \" href=\"UTD.htm?25/32/26117\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Meconium-induced umbilical cord vascular necrosis has been associated with postdates pregnancy, oligohydramnios, low cord pH, low Apgar scores, and significant neurodevelopmental delay in retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Fetal and neonatal morbidity is thought to be due to interruption of the normal blood flow in the cord causing intermittent or prolonged hypoxia in utero. There are no prospective studies to establish whether this finding should cause concern and early intervention postdelivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mass of the umbilical cord is a hematoma that is present near the cord clamp (",
"    <a class=\"graphic graphic_picture graphicRef70927 \" href=\"UTD.htm?37/22/38255\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56907 \" href=\"UTD.htm?32/16/33025\">",
"     picture 5",
"    </a>",
"    ). This is a sequela of cord clamping and of no clinical significance since it is an iatrogenic postdelivery event.",
"   </p>",
"   <p>",
"    The umbilical cord is also host to rare tumors including mature cystic teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], angiomyxomas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and intestinal polyps (ie, polypoid intestinal masses that probably develop within the vitelline duct remnant) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/19\">",
"     19",
"    </a>",
"    ]. Any of these masses can cause fetal morbidity or death in utero, if large enough, due to",
"    <span class=\"nowrap\">",
"     compression/obstruction",
"    </span>",
"    of the umbilical cord vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arterial and venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine thrombosis of umbilical artery is rare and can be followed by poor fetal outcome, such as intrauterine growth restriction or fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Remote arterial thromboses can result in the appearance of a single umbilical artery (two-vessel cord). As long as one patent artery remains, the outcome is not lethal, but an adverse outcome may result, as the thrombus can embolize to the placenta and result in loss of viable (functioning) parenchyma (see below).",
"   </p>",
"   <p>",
"    Umbilical venous thrombosis, although rare, can be fatal if complete. Partial thrombosis can embolize to the fetus, and cause cerebral or renal infarcts. Venous thrombosis occurs alone in approximately 70 percent of cases, both venous and arterial thrombosis occur in approximately 20 percent of cases, and arterial thrombosis occurs alone in 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/24\">",
"     24",
"    </a>",
"    ]. Possible causes of any umbilical thromboses include cord accidents (hypertwisting, knots, prolapse), fetal thrombophilia, peripheral cord insertion, meconium myonecrosis, and funisitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/22,25\">",
"     22,25",
"    </a>",
"    ], although many remain unexplained. Venous thrombosis has been associated with maternal diabetes, acute chorioamnionitis, and meconium-induced umbilical vascular necrosis (although umbilical artery involvement is more common).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathology of the amnion and chorion can be grouped into infections, amniotic fluid contaminants, maternal diseases, masses, and fetal diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilic (\"acute\") chorioamnionitis is probably the most common pathologic finding during placental examinations and is present in as many as one-quarter of all term placentas. Infection of the membranes appears to be the result of amniotic fluid contamination by",
"    <span class=\"nowrap\">",
"     vaginal/cervical",
"    </span>",
"    flora followed by a primarily maternal inflammatory response, although a fetal inflammatory response can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. The criteria for diagnosing histologic chorioamnionitis vary among pathologists [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/3,29\">",
"     3,29",
"    </a>",
"    ]. Some definitions involve the number of tissues affected, others have thresholds for the number of neutrophils observed. We require the presence of neutrophils in the amniotic",
"    <strong>",
"     and",
"    </strong>",
"    chorionic tissues (not just the chorionic epithelium or maternal decidua) (",
"    <a class=\"graphic graphic_picture graphicRef50692 \" href=\"UTD.htm?42/34/43558\">",
"     picture 6",
"    </a>",
"    ). Bacterial or fungal organisms may also be observed with routine or special stains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In my opinion, preterm neutrophilic chorioamnionitis is usually due to an acute infection. However, determining the duration of amniotic fluid infection by the severity of the histopathologic findings has proved unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Term chorioamnionitis may be due to other factors including non-infectious entities (for example, epidural anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/32\">",
"     32",
"    </a>",
"    ]), and may be mediated by cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune mediated (\"chronic\") chorioamnionitis is characterized by a mononuclear cell infiltrate (eg, plasma cells). Compared to the neutrophilic &ldquo;acute&rdquo; form, which is usually due to bacterial infection, chronic chorioamnionitis has a different, and often non-infectious, etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophils are required to fight bacterial infections and are therefore present in any acute or chronic bacterial infection. Lymphocytes and plasma cells may be seen in either non-infectious immune mediated disease process or in viral infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Amniotic fluid contaminants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious organisms, meconium, blood, vernix, and practically anything else in the amniotic fluid will have an impact upon the cord and membranes. These materials can be deposited on the membranes, absorbed into the membranes, or actively taken up by resident macrophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Meconium stained membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;All fetuses after 20 weeks of gestation can pass meconium. It is considered a stress related response in preterm fetuses. By comparison, in the postdates fetus meconium passage may be physiologic and is not necessarily a stress response. Meconium pigment is derived primarily from the bile pigment it contains. This pigment varies from a fluffy, light brown material to a waxy, uniform, opaque pigment like a tootsie-roll that is present in macrophages (",
"    <a class=\"graphic graphic_picture graphicRef53101 \" href=\"UTD.htm?9/62/10212\">",
"     picture 7",
"    </a>",
"    ). These differences in macrophage appearance are not related to the exposure history or the clinical course. Freshly passed meconium may coat the membranes, cord, and neonatal skin.",
"   </p>",
"   <p>",
"    Meconium appears to be toxic since it can cause amniotic epithelial necrosis, myocyte necrosis, and, in my opinion, a fetal inflammatory response. Meconium exposure is associated with a marked fetal inflammatory infiltrate from the fetal vessels in the cord",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    membranes in the absence of acute chorioamnionitis (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Parenchyma'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/7,9,10,39\">",
"     7,9,10,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infant morbidity from meconium can occur from inhalation due to gasping in utero or at birth or from umbilical vascular damage due to prolonged exposure in utero. The degree of vascular damage relates to the length of exposure: it takes at least one hour for meconium pigment to be present in the amniotic tissues; three hours for the pigment to appear in the chorion; six hours to cause amniocyte necrosis; and more than 12 hours to cause myocyte necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/7-10,39-44\">",
"     7-10,39-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masses found in the extraplacental membranes or fetal surface include remnants of the yolk sac (eg, approximately 5 mm yellow-white, well circumscribed calcified mass), amnion nodosum, hematomas, serous cysts, and fetus papyraceous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Maternal vascular and hypertensive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal vascular and hypertensive diseases are manifested in many ways in the placenta. The finding most commonly associated with preeclampsia is acute atherosis (ie, fibrinoid necrosis of the vessel wall with an accumulation of lipid-laden macrophages and a mononuclear perivascular infiltrate) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. Vascular and hypertensive diseases can cause a similar vasculitis of the decidual vessels diagnosed by the presence of any of these findings: vascular ectasia, fibrinoid necrosis of the vessel wall, peripheral mononuclear cell infiltrate, and thrombi within the vessel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .) Clarification of the specific histopathologic findings is the same as for any cause of uterine vascular insufficiency to the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/51\">",
"     51",
"    </a>",
"    ]. Studies of the significance of placental insufficiency show its relevance to fetal neurologic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21929?source=see_link\">",
"     \"Placental pathology in cases of neurologically impaired infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fetal disorders affecting the membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal anomalies that involve exposure of fetal viscera to the amnion (eg, exstrophies, ectopia cordis, gastroschisis) can cause metaplasia of the amniotic epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/30,52\">",
"     30,52",
"    </a>",
"    ]. The cells become expanded with a foamy microvesicular change.",
"   </p>",
"   <p>",
"    Renal disorders, such as renal agenesis and prune belly syndrome, result in severe and prolonged oligohydramnios. The lack of amniotic fluid allows the fetal skin to contact the amnion, resulting in abrasion of the amnion and deposition of fetal squamous cells on the eroded areas. These areas appear as white nodules on the fetal surface (ie, amnion nodosum) (",
"    <a class=\"graphic graphic_picture graphicRef78284 \" href=\"UTD.htm?33/45/34515\">",
"     picture 8",
"    </a>",
"    ), but spare the umbilical cord [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inborn errors of metabolism, in which the storage material accumulates in the amniotic cells, also affect the amnion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hemosiderin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all brown pigment is meconium. Blood in the amniotic fluid from chronic abruption can cause hemosiderin deposition in the amniotic macrophages. This pigment differs from meconium because of its yellow and crystalline hue, obviating the necessity for special stains in most cases. I obtain iron stains when the clinical history suggests passage of meconium or in-utero stress or in suspicious cases, such as when the brown pigment is",
"    <span class=\"nowrap\">",
"     coppery/birefringent,",
"    </span>",
"    there is excessive pigment, or in cases in which the gestational age is less than 30 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vernix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postdates infants have extensive vernix and deposit this material on or between the membranes. The classic gross appearance is chalky white caseous material on the placenta; histologic findings of fetal squamous cells, mucin, and hair are confirmatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PARENCHYMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenchymal lesions can result from either a fetal or maternal source, since both circulations perfuse the placenta. Neurologic impairment and cerebral palsy in children have been correlated with the presence of severe placental vascular lesions, such as fetal thrombotic vasculopathy, chronic (lympho-histiocytic) villitis with obliterative fetal vasculopathy, chorioamnionitis (neutrophilic) with severe fetal vasculitis, meconium-associated fetal vascular necrosis. In one study, one or more of these lesions was found in the placentas of 51 percent of neurologically impaired term infants (n = 125) who were the focus of clinical negligence litigation versus 10 percent of controls (250 consecutive singleton deliveries &ge;36 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/54\">",
"     54",
"    </a>",
"    ]. Index infants were more likely to be growth restricted (14 versus 8 percent) and exhibit 5-minute Apgar scores &lt;7 (73 versus 1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Villitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both neutrophilic (\"acute\") and lympho-histiocytic (\"chronic\") villitis are inflammatory infiltrates involving the placental parenchyma. The specific diagnosis is based upon the nature and type of inflammatory",
"    <span class=\"nowrap\">",
"     infiltrate.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acute villitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilic/acute",
"    villitis is a specific gross and histologic feature of",
"    <span class=\"nowrap\">",
"     micro/macro",
"    </span>",
"    neutrophilic abscesses in the placental parenchyma and is often accompanied by neutrophilic chorioamnionitis (",
"    <a class=\"graphic graphic_picture graphicRef56641 \" href=\"UTD.htm?36/52/37705\">",
"     picture 9",
"    </a>",
"    ). It is a rare finding, however, as expected given the primarily neutrophilic response, it is typically associated with a bacterial infection, almost always secondary to listerial infections, but sometimes due to streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/7,9,10,39\">",
"     7,9,10,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link&amp;anchor=H18#H18\">",
"     \"Placental infections\", section on 'Listeria monocytogenes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lympho-histiocytic (\"chronic\") villitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic villitis refers to a mononuclear (primarily histiocytes and lymphocytes) cell infiltrate within or around the villi (",
"    <a class=\"graphic graphic_picture graphicRef77237 \" href=\"UTD.htm?41/50/42793\">",
"     picture 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. It is a common, usually nonspecific, finding detected in approximately 10 percent of term placentas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/37,57\">",
"     37,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of chronic villitis appears to be the response of the maternal host to the fetal allograft. The mononuclear cells are maternal in origin and are probably responding to a fetal antigen expressed by the villi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/58\">",
"     58",
"    </a>",
"    ]. In some cases, the fetus is compromised by necrosis of the villi by maternal white cells; this process is commonly manifested clinically as intrauterine growth restriction (IUGR) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. It is also possible that products of villous inflammation enter the fetal vasculature and have a systemic effect on fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/61\">",
"     61",
"    </a>",
"    ]. Chronic villitis has also been associated with fertility problems, untreated neonatal alloimmune thrombocytopenia, and neonatal neurological impairment (when associated with obliterative fetal vasculopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/54,59,62,63\">",
"     54,59,62,63",
"    </a>",
"    ]. It rarely recurs in future pregnancies.",
"   </p>",
"   <p>",
"    One group reported a favorable response to treatment with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    during pregnancy in two patients with histories of fetal deaths and chronic villitis of unknown etiology or chronic intervillositis of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/64\">",
"     64",
"    </a>",
"    ]. The use of immunosuppression in these patients should be considered investigational.",
"   </p>",
"   <p>",
"    An infectious etiology is the cause of a small (less than five percent) subset of cases of chronic villitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. TORCH infections (ie, Toxoplasmosis, Other, Rubella, Cytomegalovirus, Herpes) are the usual source. This type of chronic villitis is associated with other abnormal pathological or clinical findings, such as plasma cell deciduitis, stillbirth, IUGR, or hydrops. The diagnosis is made by routine hematoxylin-eosin or immunohistochemical stains for viral markers or spirochetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ischemic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the maternal or fetal vasculature can reduce blood flow from the placenta to the fetus. In either case, impaired availability of oxygen and nutrients to the fetus can lead to fetal compromise. One mechanism may involve changes in regulation of apoptosis of villous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extravillous trophoblast [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Placental \"underperfusion\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, histopathologic findings in the placenta associated with maternal hypertensive diseases have been attributed to \"underperfusion,\" although the damage may be more related to hypertensive injury (pressure related) than to true underperfusion or ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Chronic maternal \"underperfusion\" of fetal villi often results in a small (eg, placental weight is &lt;10th percentile) ischemic placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. The villi become smaller and smaller as ischemia progresses and numerous large syncytial trophoblastic knots develop.",
"   </p>",
"   <p>",
"    Chronic \"underperfusion\" ultimately results in placental infarcts (",
"    <a class=\"graphic graphic_picture graphicRef51550 \" href=\"UTD.htm?36/62/37865\">",
"     picture 11",
"    </a>",
"    ). Peripheral infarcts on the maternal side of the placenta are common at term and usually not clinically significant. Perinatal morbidity is associated with infarcts of more than 5 percent of the placental mass or greater than 3 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Infarcts are considered clinically severe (eg, associated with",
"    <span class=\"nowrap\">",
"     IUGR/stillbirths)",
"    </span>",
"    if 20 percent or more of the placenta is affected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific histopathologic findings that correlate with maternal \"underperfusion\" include: increased syncytial knots",
"    <span class=\"nowrap\">",
"     (&gt;1/3",
"    </span>",
"    to 5 terminal villi",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &gt;10 nuclei per knot), villous agglutination (infarcts with villi collapsing on one another), distal villous hypoplasia (reduced numbers of villi resulting in increased intervillous space), increased intervillous fibrin (filling the slide), sclerotic narrowing of arteries and arterioles, and sheets of intermediate trophoblast along the basal plate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/51\">",
"     51",
"    </a>",
"    ]; although the significance of the findings and their relationship to clinical disease are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infarcts consist of collapsed maternal intervillous spaces and necrotic villi, usually involving the maternal floor. These findings are nonspecific and can occur with maternal hypertensive disorders (preeclampsia, chronic hypertension), uterine anomalies, maternal cardiovascular disease, and maternal hereditary and acquired thrombophilias.",
"   </p>",
"   <p>",
"    As discussed above, maternal vascular and hypertensive diseases are manifested in many ways in the placenta. The finding most commonly associated with preeclampsia is foamy macrophages within the vessel wall (ie, acute atherosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/82-87\">",
"     82-87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fetal vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta's dual circulation (maternal and fetal) can be compromised by either maternal vascular or fetal vascular flow abnormalities, including absent flow, slow flow, and hemorrhage. The maternal side of this biology results in classic lesions of placental infarcts, abruptio placentae, and ischemic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/51\">",
"     51",
"    </a>",
"    ]. The pathology associated with vascular flow abnormalities on the fetal side are known to be significant indicators of fetal well being and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/88\">",
"     88",
"    </a>",
"    ] and have been well-characterized and classified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organized thrombi in fetal vessels &mdash; One can occasionally see organized mural occlusive or nonocclusive thromboemboli in the fetal vessels of the placenta including the umbilical cord, chorionic plate, and villi. The presence of chorionic plate vascular thrombi should raise suspicions of congenital viral infections, especially in the setting of premature delivery, hydrops, stillbirth, or villitis. Both CMV and HSV placentitis have an association with chorionic plate vascular thrombi [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/90\">",
"       90",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"       \"Placental infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avascular villi &mdash; The villi become necrotic if the fetus stops perfusing them, but the maternal intervillous spaces are maintained since maternal blood flow is not affected. Avascular villi are usually the result of fetal vascular damage (eg, a membranous cord insertion or severe chorioamnionitis with vascular involvement) or fetal thromboemboli (",
"      <a class=\"graphic graphic_picture graphicRef77237 \" href=\"UTD.htm?41/50/42793\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hemorrhagic endovasculitis &mdash; Hemorrhagic endovasculitis refers to a particular type of thromboemboli in which the villous vessels are occluded and contain extravasated red blood cells (",
"      <a class=\"graphic graphic_picture graphicRef50997 \" href=\"UTD.htm?31/19/32056\">",
"       picture 12",
"      </a>",
"      ). This lesion is thought to be due to slow flow from the fetus, as in cardiac failure or polycythemia. This finding is common among stillbirths, although in these cases it is difficult to conclude whether the finding preceded and may have contributed to the fetal death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetal thrombotic vasculopathy is nearly always present in placentas from stillbirths but do occur frequently in live births. The differential diagnosis includes: anatomic obstruction (true knots of the umbilical cord, membranous vessels), inflammatory injury to vessels (as in the \"phlebitis\" present in some cases of neutrophilic chorioamnionitis and the small vessels compromised in neutrophilic or lympho-histiocytic villitis), toxic causes (meconium myonecrosis, infant of insulin requiring diabetic mother), sepsis with disseminated intravascular coagulation, polycythemia, cardiac failure, and in inherited fetal coagulopathy (eg, factor V Leiden) and congenital stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/25,44,82-87,91-93\">",
"     25,44,82-87,91-93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenchymal masses include infarcts and abscesses, intervillous thrombi, placental tumors, and metastatic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Intervillous thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervillous thrombi (IVT) are laminated red blood cells and fibrin that fill the maternal space separating the villi (",
"    <a class=\"graphic graphic_picture graphicRef74960 \" href=\"UTD.htm?2/34/2597\">",
"     picture 13",
"    </a>",
"    ). Grossly, IVTs appear as laminated jelly-like to firm lesions from",
"    <span class=\"nowrap\">",
"     pink/tan",
"    </span>",
"    to dark red in color, depending upon the age of the thrombus. These lesions are due to fetal hemorrhage into the maternal space and are quite common and usually benign. They occur at higher frequency in pregnancies complicated by Rh and ABO incompatibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. Other signs of fetal anemia (eg, circulating immature red blood cells and hydrops) should be present in severe cases of chronic fetomaternal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/98\">",
"     98",
"    </a>",
"    ], but are not observed with acute hemorrhage. Three or more IVTs or any IVT associated with a stillbirth warrants investigation for fetomaternal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Chorioangioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental neoplasms are generally benign neoplasms such as chorioangiomas (",
"    <a class=\"graphic graphic_picture graphicRef67130 \" href=\"UTD.htm?36/22/37225\">",
"     picture 14",
"    </a>",
"    ) and vascular neoplasms of the stem villi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/99-109\">",
"     99-109",
"    </a>",
"    ]. Teratomas and other much rarer lesions also may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/110-114\">",
"     110-114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chorioangiomas range from microscopic lesion(s) to large masses. Those greater than 4 to 5 cm in diameter carry a risk of fetal morbidity due to high output heart failure from arteriovenous shunting, platelet trapping, consumptive coagulopathy, and preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/109,115\">",
"     109,115",
"    </a>",
"    ]. Polyhydramnios is also common. An association between placental chorioangiomas and visceral hemangiomas in the",
"    <span class=\"nowrap\">",
"     fetus/infant",
"    </span>",
"    is controversial.",
"   </p>",
"   <p>",
"    In a case reports and series, injection of absolute alcohol and endoscopic laser ablation have been used successfully to block the vascular supply to the tumor in pregnancies remote from term [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Metastatic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic neoplasms can result from any hematogenously spread malignant neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/116-127\">",
"     116-127",
"    </a>",
"    ]. Grossly, they all appear as an infarct-like mass lesion on the maternal side of the placenta. In one review, 72 of 87 metastatic neoplasms involved the placenta only, 10 were metastatic just to the fetus, and five affected both the placenta and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/124\">",
"     124",
"    </a>",
"    ]. The primary sites consisted of melanoma in 27 cases, breast cancer in 15,",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    in 15, and lung cancer in 10. Fetal involvement was most common with metastatic melanoma (6 of 27), and five of these six infants died of the disease. No metastatic breast carcinomas affected the fetus.",
"   </p>",
"   <p>",
"    Fetal malignant neoplasms, such as neuroblastoma, can metastasize to the placenta as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. Benign (non-neoplastic) nevus cells can populate the villi, which is a dramatic microscopic finding of no clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36807005\">",
"    <span class=\"h3\">",
"     Villous maturational arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The villi of mature placentas reflect a full range of sizes with an orderly progression from the large stem villi with muscularized vessels down to the small terminal villi, which are the smallest villi and contain one to three capillaries, vasculosyncytial membranes, and syncytiotrophoblastic knots (",
"    <a class=\"graphic graphic_picture graphicRef62758 \" href=\"UTD.htm?2/0/2056\">",
"     picture 15",
"    </a>",
"    ). At term, terminal villi should predominate. Villous maturational arrest refers to term placentas that have a paucity or absence of terminal villi, such that most of the villi are intermediate in size with increased capillaries and an absence of vasculosyncytial membranes (",
"    <a class=\"graphic graphic_picture graphicRef72450 \" href=\"UTD.htm?29/30/30184\">",
"     picture 16",
"    </a>",
"    ). This finding has been linked to fetal demise, possibly because the absence of vasculosyncytial membranes increases the distance (ie, decreases the efficiency) of",
"    <span class=\"nowrap\">",
"     oxygen/nutrient",
"    </span>",
"    transfer to the fetus, resulting in decreased placental capacity to meet the fetal demands [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3685445\">",
"    <span class=\"h3\">",
"     Chorangiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorangiosis refers to an increase in the number of vascular channels in noninfarcted, nonischemic areas of the placenta. It is uncommon, and thought to be related to long-standing hypoxia. It has been associated with stillbirth, cord problems, congenital anomalies, and pregnancies at high altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/102,131-133\">",
"     102,131-133",
"    </a>",
"    ]. Chorangiosis can be confused with placental villous congestion, but in the latter, the vessels are distended without an increase in number of vessels per villous. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3685272\">",
"    <span class=\"h3\">",
"     Maternal floor infarct and massive chronic intervillositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal floor infarct (MFI) and massive chronic intervillositis (MCI) are two parenchymal disorders associated with perinatal morbidity and mortality and maternal recurrence. They are probably related to or part of a spectrum of maternal immunologic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h4\">",
"     Maternal floor infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal floor corresponds to the anatomic region of the placental disk attached to the maternal surface of the uterine cavity. It includes the most basal villi, Nitabuch's membrane, the placental implantation site, and the decidual basalis. MFI refers to a process in which a thick band of fibrinoid material is deposited along the maternal floor of the placenta, thereby obstructing maternal blood flow through the placenta to the fetal villi (",
"    <a class=\"graphic graphic_picture graphicRef59608 \" href=\"UTD.htm?15/17/15637\">",
"     picture 17",
"    </a>",
"    ). The lesion has been associated with both an elevated maternal serum alpha-fetoprotein and recurrence in subsequent pregnancies. The fetal sequelae include IUGR and stillbirth due to uteroplacental insufficiency. The etiology of MFI is unknown, but is thought to be an extreme form of host versus graft reaction to the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/37,134-138\">",
"     37,134-138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h4\">",
"     Massive chorionic intervillositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCI refers to the presence of massive amounts of intervillous and perivillous fibrin associated with a marked maternal histiocyte infiltration (",
"    <a class=\"graphic graphic_picture graphicRef58193 \" href=\"UTD.htm?35/62/36841\">",
"     picture 18",
"    </a>",
"    ). This lesion is distinctive in the term placenta, but is more commonly present in first and second trimester losses. It has been reported to recur in future pregnancies, but the literature describing these cases is sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/139-141\">",
"     139-141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Abruptio placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the diagnosis of acute abruptio placenta is made clinically. Histological findings, such as diffuse retromembranous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intradecidual hemorrhages, irregular basal intervillous thrombi, and recent villous stromal hemorrhage, are not specific for the diagnosis. The pathologic findings in cases of subacute abruption are an organizing retroplacental hematoma with overlying recent villous infarction. Recent infarcts are characterized by preservation of villous stromal architecture, eosinophilic degeneration of the syncytiotrophoblast, and villous agglutination with scattered intervillous neutrophils. These infarcts take approximately four to six hours to develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SELECTED PLACENTAL FINDINGS AND DIAGNOSES OF PERINATAL AND MEDICOLEGAL IMPORTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some placental findings are of clinical importance either to the mother or",
"    <span class=\"nowrap\">",
"     fetus/infant.",
"    </span>",
"    Many of these findings are significant enough to warrant an immediate phone call to the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Acute versus chronic stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unstressed or acutely stressed gestation should have a placenta of normal weight. Chronic stress often results in a small placenta (&lt;10th percentile for gestational age) (",
"    <a class=\"graphic graphic_table graphicRef72177 \" href=\"UTD.htm?7/12/7374\">",
"     table 1",
"    </a>",
"    ), but may produce a very heavy placenta (&gt;99th percentile) in pregnancies complicated by maternal diabetes or fetal hydrops. The placental weight, therefore, is a critical parameter of in-utero well-being.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute stress refers to stress of at least one but less than 24 hours duration. Placental pathologic findings include meconium pigmentation (if less than 40 weeks of gestation) and acute villous edema [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/31,142\">",
"       31,142",
"      </a>",
"      ]. Although some authorities believe that the fetus can release immature red blood cells (nucleated red blood cells) in as short a time as hours, I feel an increased nucleated red blood cell count in the newborn is more consistent with chronic stress in utero [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/31,142\">",
"       31,142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic stress refers to stress lasting days to weeks. The best indicator of chronic stress is a placental weight less than the 10th percentile; other findings include infarcts, amnion nodosum, erythroblastosis, hydrops placentalis, and chronic villitis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/143-145\">",
"       143-145",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Single umbilical artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of single umbilical artery (SUA) is low, occurring in 392 of 64,047 infants (0.61 percent) in one of the largest series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/146\">",
"     146",
"    </a>",
"    ]. There is a well documented association of SUA with fetal anomalies (generally genitourinary, cardiac, or gastrointestinal). The prevalence of congenital abnormalities in affected fetuses and infants ranges from 10 to 30 percent; rates at the upper end of the range were reported in series that included patients referred because of prenatally detected anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/146-148\">",
"     146-148",
"    </a>",
"    ]. The rate of anomalies was 66 percent in series limited to abortuses, fetal deaths, and autopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/147\">",
"     147",
"    </a>",
"    ]. In the large series previously described, both cardiac anomalies and renal anomalies were significantly more prevalent in infants with SUA than those without SUA (cardiac anomalies 7.1 versus 0.4 percent, renal anomalies 4.8 versus 1.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/146\">",
"     146",
"    </a>",
"    ]. A significant increase in prevalence of growth restriction has also been reported, but inconsistently [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/146,149-153\">",
"     146,149-153",
"    </a>",
"    ]. The Society of Obstetricians and Gynaecologists of Canada recommends that appropriate fetal growth be confirmed through clinical evaluation, with follow-up ultrasound if clinically warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The left artery appears to be absent more often than the right, but outcome does not appear to be associated with whether the left or right artery is missing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetuses with a single umbilical artery noted on ultrasound should be carefully screened for other anomalies via antenatal sonography and the neonate should be closely examined at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/156-160\">",
"     156-160",
"    </a>",
"    ]. Prenatal ultrasound examination should be comprehensive, but specialist fetal echocardiography that goes beyond the standard four-chamber view and views of the great arteries does not appear to be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/161\">",
"     161",
"    </a>",
"    ]. The number and location of kidneys should be documented by antenatal or postnatal sonography. However, the current data do not justify extensive urologic radiographic investigations in asymptomatic newborns having an isolated SUA anomaly unless additional risk factors for malformations exist [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/147,162\">",
"     147,162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of aneuploidy with isolated SUA does not appear to be increased, so most experts do not recommend routine chromosomal analysis if there are no other malformations or other indications for genetic amniocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/148,154,158,163-165\">",
"     148,154,158,163-165",
"    </a>",
"    ]. In a series of 643 fetuses with SUA, the anomaly was isolated in 424 fetuses and none of these fetuses had a chromosomal abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/148\">",
"     148",
"    </a>",
"    ]. The same authors&rsquo; review of the literature found 809 cases of isolated SUA of which 6 had an abnormal karyotype (three trisomy 18 and three trisomy 21). Fetal karyotype is indicated when additional malformations are detected. In this series, the aneuploidy rates with one major defect and multiple defects were 4 and 50 percent, respectively. Some investigators also suggest follow-up ultrasound examination to screen for growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An isolated finding of SUA should not influence the timing or route of delivery. Short- and long-term physical and neurological development of the child with isolated SUA appears to be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Disorders affecting the fetus and newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta is a window that permits the physician to study the intrauterine environment of the fetus and some of the fetal responses to disease. Some examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal thromboembolic events, meconium myonecrosis, and",
"      <span class=\"nowrap\">",
"       funisitis/umbilical",
"      </span>",
"      cord vasculitis are placental diagnoses associated with perinatal morbidity. Early newborn intervention may diminish the risk of neurodevelopmental compromise [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/82,83,91-93,167-169\">",
"       82,83,91-93,167-169",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inborn errors of metabolism such as GM1 gangliosidosis (type 1) will present with placental findings, even when the neonate appears normal [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/53\">",
"       53",
"      </a>",
"      ]. Diagnosis at placental examination will allow for early intervention and reproductive counseling.",
"     </li>",
"     <li>",
"      Congenital infections such as cytomegalovirus, herpes simplex virus, listeriosis, and toxoplasmosis can be diagnosed on placental examination. Neonatal and maternal intervention by treatment or quarantine can be initiated, as appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"       \"Placental infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic syndromes may display characteristic features. Beckwith-Wiedemann syndrome, as an example, is associated with placentomegaly and is important to diagnose due to the high association of the syndrome with congenital and pediatric malignancies (eg, Wilms tumor). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"       \"Beckwith-Wiedemann syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fetal hemolysis due to ABO incompatibility or other red blood cell isoimmunization can persist for weeks postdelivery. The presence of multiple intervillous thrombi and fetal normoblastemia on placental examination can suggest this problem in infants who appear well or mildly jaundiced, thus allowing appropriate evaluation, treatment, and counseling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link\">",
"       \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the placenta can provide information regarding the etiology of neurologically impaired infants and children [",
"      <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/170\">",
"       170",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21929?source=see_link\">",
"       \"Placental pathology in cases of neurologically impaired infants\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Maternal diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal disease can extend to the placenta or first present in that organ. Choriocarcinoma is a placental neoplasm, sometimes detected on placental examination in otherwise unremarkable pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/171,172\">",
"     171,172",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=see_link\">",
"     \"Gestational trophoblastic disease: Pathology\"",
"    </a>",
"    .) Other malignant neoplasms can also appear initially in the placenta. As an example, I have seen lymphoma and breast cancer with their first presentation as a placental metastasis.",
"   </p>",
"   <p>",
"    Maternal immunologic dysfunction resulting in maternal floor infarction or massive chronic intervillositis is a disorder associated with perinatal morbidity and mortality and maternal recurrence. Diagnosis and possible treatment is dependent upon placental examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Recurrent preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of placental histology in recurrent preterm birth reported neutrophilic inflammation of the membranes, chorionic plate, and umbilical cord in 50 percent or more of pregnancies with recurrent spontaneous preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/173\">",
"     173",
"    </a>",
"    ]. Inflammation leading to thromboses in chorionic and umbilical vessels was not uncommon, possibly due to activation of the clotting cascade as a result of infection. The thrombosis began in the intima of chorionic veins and umbilical vessels, ultimately resulting in villous atrophy. Of note, this is an uncommon cause of thromboses of large placental veins, which is usually secondary to obstruction to venous return.",
"   </p>",
"   <p>",
"    By comparison, the most prominent histologic finding observed in medically indicated recurrent preterm births was diffuse decidual leukocytoclastic necrosis (DDLN, also called laminar necrosis); mononuclear inflammation was often present, as well. DDLN has been associated with vascular insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental examination in multifetal gestation helps to determine zygosity, but may not be conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/174-176\">",
"     174-176",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5306?source=see_link&amp;anchor=H1584080997#H1584080997\">",
"     \"Twin pregnancy: Labor and delivery\", section on 'Monozygotic or dizygotic?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When histologic chorioamnionitis is diagnosed in the sac of a presenting twin, the nonpresenting twin is usually also affected in monochorionic, but not dichorionic, placentas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/46/27370/abstract/177\">",
"     177",
"    </a>",
"    ]. However in the presence of severe inflammation with both chorioamnionitis and funisitis, the nonpresenting twin is usually spared only if the placentas are dichorionic and separate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Funisitis involving only the external surface of the cord and Wharton's jelly is most likely of maternal origin. Inflammatory cells seen migrating through the fetal vessels in the cord are evidence of a fetal response and are diagnostic of systemic fetal inflammatory response syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Acute/neutrophilic",
"      </span>",
"      chorioamnionitis is usually bacteria-mediated and is the most common pathologic finding during placental examination.",
"      <span class=\"nowrap\">",
"       Chronic/mononuclear",
"      </span>",
"      chorioamnionitis is characterized by an mononuclear cell infiltrate (eg, plasma cells) and often has a noninfectious etiology. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chorioamnionitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meconium is a toxin and may induce umbilical cord vascular necrosis, amniotic epithelial necrosis, myocyte necrosis, and a fetal inflammatory response (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Meconium stained cord'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Meconium stained membranes'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Both neutrophilic and lympho-histiocytic (\"acute\" and \"chronic\") villitis are inflammatory infiltrates involving the placental parenchyma, but they are due to different etiologies. The specific diagnosis is based upon the nature and type of inflammatory infiltrate. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Villitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral infarcts on the maternal side of the placenta are common at term and usually not clinically significant. Perinatal morbidity is associated with infarcts of more than 5 percent of the placental mass or greater than 3 cm in diameter. Infarcts are considered clinically severe (eg, associated with",
"      <span class=\"nowrap\">",
"       IUGR/stillbirths)",
"      </span>",
"      if 20 percent or more of the placenta is affected. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Ischemic lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Investigation for fetomaternal hemorrhage is suggested if three or more intervillous thrombi are present or if an intervillous thrombus is associated with a stillbirth. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Intervillous thrombi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chorioangiomas greater than 4 to 5 cm in diameter carry a risk for fetal morbidity; therefore, serial ultrasound examinations of the fetus are suggested. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Chorioangioma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Fetuses/infants",
"      </span>",
"      with a single umbilical artery should be examined carefully because they are at increased risk of congenital anomalies. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Single umbilical artery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/1\">",
"      Jauniaux E, De Munter C, Vanesse M, et al. Embryonic remnants of the umbilical cord: morphologic and clinical aspects. Hum Pathol 1989; 20:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/2\">",
"      Yoon BH, Romero R, Park JS, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 2000; 183:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/3\">",
"      Redline RW, Faye-Petersen O, Heller D, et al. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 2003; 6:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/4\">",
"      Redline RW. Placental pathology and cerebral palsy. Clin Perinatol 2006; 33:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/5\">",
"      Qureshi F, Jacques SM, Bendon RW, et al. Candida funisitis: A clinicopathologic study of 32 cases. Pediatr Dev Pathol 1998; 1:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/6\">",
"      Mittendorf R, Montag AG, MacMillan W, et al. Components of the systemic fetal inflammatory response syndrome as predictors of impaired neurologic outcomes in children. Am J Obstet Gynecol 2003; 188:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/7\">",
"      Altshuler G, Arizawa M, Molnar-Nadasdy G. Meconium-induced umbilical cord vascular necrosis and ulceration: a potential link between the placenta and poor pregnancy outcome. Obstet Gynecol 1992; 79:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/8\">",
"      Lewis SH, Gilbert-Barness E. The placenta and its significance in neonatal outcome. Adv Pediatr 1998; 45:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/9\">",
"      Naeye RL. Can meconium in the amniotic fluid injure the fetal brain? Obstet Gynecol 1995; 86:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/10\">",
"      Miller PW, Coen RW, Benirschke K. Dating the time interval from meconium passage to birth. Obstet Gynecol 1985; 66:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/11\">",
"      Kreczy A, Alge A, Menardi G, et al. Teratoma of the umbilical cord. Case report with review of the literature. Arch Pathol Lab Med 1994; 118:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/12\">",
"      Driscoll SG. Umbilical cord teratoma. Hum Pathol 1985; 16:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/13\">",
"      Smith D, Majmudar B. Teratoma of the umbilical cord. Hum Pathol 1985; 16:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/14\">",
"      Ghidini A, Romero R, Eisen RN, et al. Umbilical cord hemangioma. Prenatal identification and review of the literature. J Ultrasound Med 1990; 9:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/15\">",
"      Kamitomo M, Sueyoshi K, Matsukita S, et al. Hemangioma of the umbilical cord: stenotic change of the umbilical vessels. Fetal Diagn Ther 1999; 14:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/16\">",
"      S&oslash;ndergaard G. Hemangioma of the umbilical cord. Acta Obstet Gynecol Scand 1994; 73:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/17\">",
"      Carvounis EE, Dimmick JE, Wright VJ. Angiomyxoma of umbilical cord. Arch Pathol Lab Med 1978; 102:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/18\">",
"      Yavner DL, Redline RW. Angiomyxoma of the umbilical cord with massive cystic degeneration of Wharton's jelly. Arch Pathol Lab Med 1989; 113:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/19\">",
"      Lee MC, Aterman K. An intestinal polyp of the umbilical cord. Am J Dis Child 1968; 116:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/20\">",
"      Klaritsch P, Haeusler M, Karpf E, et al. Spontaneous intrauterine umbilical artery thrombosis leading to severe fetal growth restriction. Placenta 2008; 29:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/21\">",
"      Solano S&aacute;nchez SR, Baquera Heredia JJ, Reyes Cuervo H, Buen Abad EI. [Umbilical artery thrombosis. A report of a case and review of the literature]. Ginecol Obstet Mex 2005; 73:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/22\">",
"      Sato Y, Benirschke K. Umbilical arterial thrombosis with vascular wall necrosis: clinicopathologic findings of 11 cases. Placenta 2006; 27:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/23\">",
"      Afriat R, Bidat L, Fortier F, et al. [Prenatal diagnosis of spontaneous thrombosis of the umbilical artery during the third trimester of pregnancy. Two cases with surviving infants]. J Gynecol Obstet Biol Reprod (Paris) 1995; 24:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/24\">",
"      Heifetz SA. Thrombosis of the umbilical cord: analysis of 52 cases and literature review. Pediatr Pathol 1988; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/25\">",
"      Ariel I, Anteby E, Hamani Y, Redline RW. Placental pathology in fetal thrombophilia. Hum Pathol 2004; 35:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/26\">",
"      Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993; 36:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/27\">",
"      Quinn PA, Butany J, Taylor J, Hannah W. Chorioamnionitis: its association with pregnancy outcome and microbial infection. Am J Obstet Gynecol 1987; 156:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/28\">",
"      Zhang JM, Kraus FT, Aquino TI. Chorioamnionitis: a comparative histologic, bacteriologic, and clinical study. Int J Gynecol Pathol 1985; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/29\">",
"      Holzman C, Lin X, Senagore P, Chung H. Histologic chorioamnionitis and preterm delivery. Am J Epidemiol 2007; 166:786.",
"     </a>",
"    </li>",
"    <li>",
"     Benirschke, K, Kaufman, P, Baergen, RN. The pathology of the human placenta, New York: Springer-Verlag 2006.",
"    </li>",
"    <li>",
"     Fox, H. Pathology of the Placenta, In: Major Problems in Pathology, 2nd ed, W.B. Saunders, London 1997. p. 488.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/32\">",
"      Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/33\">",
"      Aaltonen R, Heikkinen T, Hakala K, et al. Transfer of proinflammatory cytokines across term placenta. Obstet Gynecol 2005; 106:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/34\">",
"      Baergen R, Benirschke K, Ulich TR. Cytokine expression in the placenta. The role of interleukin 1 and interleukin 1 receptor antagonist expression in chorioamnionitis and parturition. Arch Pathol Lab Med 1994; 118:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/35\">",
"      Hagberg H, Wennerholm UB, S&auml;vman K. Sequelae of chorioamnionitis. Curr Opin Infect Dis 2002; 15:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/36\">",
"      Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev 2007; 65:S194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/37\">",
"      Gersell DJ. Chronic villitis, chronic chorioamnionitis, and maternal floor infarction. Semin Diagn Pathol 1993; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/38\">",
"      Jacques SM, Qureshi F. Chronic chorioamnionitis: a clinicopathologic and immunohistochemical study. Hum Pathol 1998; 29:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/39\">",
"      Mazor M, Furman B, Wiznitzer A, et al. Maternal and perinatal outcome of patients with preterm labor and meconium-stained amniotic fluid. Obstet Gynecol 1995; 86:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/40\">",
"      Altshuler G, Hyde SR. Clinicopathologic implications of placental pathology. Clin Obstet Gynecol 1996; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/41\">",
"      Altshuler G. Role of the placenta in perinatal pathology (revisited). Pediatr Pathol Lab Med 1996; 16:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/42\">",
"      Mayer DC, Chescheir NC, Spielman FJ. Increased intrapartum antibiotic administration associated with epidural analgesia in labor. Am J Perinatol 1997; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/43\">",
"      Simon C, Schr&ouml;der H, Weisner D, et al. Bacteriological findings after premature rupture of the membranes. Arch Gynecol Obstet 1989; 244:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/44\">",
"      Stevens NG, Sander CH. Placental hemorrhagic endovasculitis: risk factors and impact on pregnancy outcome. Int J Gynaecol Obstet 1984; 22:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/45\">",
"      Khong TY. Acute atherosis in pregnancies complicated by hypertension, small-for-gestational-age infants, and diabetes mellitus. Arch Pathol Lab Med 1991; 115:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/46\">",
"      Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/47\">",
"      Khong TY, Pearce JM, Robertson WB. Acute atherosis in preeclampsia: maternal determinants and fetal outcome in the presence of the lesion. Am J Obstet Gynecol 1987; 157:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/48\">",
"      Davies BR. Decidual vascular lesions of fibrinoid necrosis/atherosis. Am J Obstet Gynecol 1982; 144:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/49\">",
"      Soma H, Yoshida K, Mukaida T, Tabuchi Y. Morphologic changes in the hypertensive placenta. Contrib Gynecol Obstet 1982; 9:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/50\">",
"      Robertson WB, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. Perspect Nephrol Hypertens 1976; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/51\">",
"      Redline RW, Boyd T, Campbell V, et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 2004; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/52\">",
"      Grafe MR, Benirschke K. Ultrastructural study of the amniotic epithelium in a case of gastroschisis. Pediatr Pathol 1990; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/53\">",
"      Roberts DJ, Ampola MG, Lage JM. Diagnosis of unsuspected fetal metabolic storage disease by routine placental examination. Pediatr Pathol 1991; 11:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/54\">",
"      Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. Am J Obstet Gynecol 2005; 192:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/55\">",
"      Boog G. Chronic villitis of unknown etiology. Eur J Obstet Gynecol Reprod Biol 2008; 136:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/56\">",
"      Redline RW. Villitis of unknown etiology: noninfectious chronic villitis in the placenta. Hum Pathol 2007; 38:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/57\">",
"      Althsuler G. Placental villitis of unknown etiology: harbinger of serious disease? A four month's experience of nine cases. J Reprod Med 1973; 11:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/58\">",
"      Redline RW, Patterson P. Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells. Am J Pathol 1993; 143:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/59\">",
"      Labarrere C, Althabe O. Chronic villitis of unknown aetiology in recurrent intrauterine fetal growth retardation. Placenta 1987; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/60\">",
"      Becroft DM, Thompson JM, Mitchell EA. Placental villitis of unknown origin: epidemiologic associations. Am J Obstet Gynecol 2005; 192:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/61\">",
"      Heyborne KD, McGregor JA, Henry G, et al. Interleukin-10 in amniotic fluid at midtrimester: immune activation and suppression in relation to fetal growth. Am J Obstet Gynecol 1994; 171:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/62\">",
"      Althaus J, Weir EG, Askin F, et al. Chronic villitis in untreated neonatal alloimmune thrombocytopenia: an etiology for severe early intrauterine growth restriction and the effect of intravenous immunoglobulin therapy. Am J Obstet Gynecol 2005; 193:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/63\">",
"      Russell P, Atkinson K, Krishnan L. Recurrent reproductive failure due to severe placental villitis of unknown etiology. J Reprod Med 1980; 24:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/64\">",
"      Boog G, Le Vaillant C, Alnoukari F, et al. [Combining corticosteroid and aspirin for the prevention of recurrent villitis or intervillositis of unknown etiology]. J Gynecol Obstet Biol Reprod (Paris) 2006; 35:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/65\">",
"      Nakamura Y, Sakuma S, Ohta Y, et al. Detection of the human cytomegalovirus gene in placental chronic villitis by polymerase chain reaction. Hum Pathol 1994; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/66\">",
"      Popek EJ. Granulomatous villitis due to Toxoplasma gondii. Pediatr Pathol 1992; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/67\">",
"      Redline RW. Recurrent villitis of bacterial etiology. Pediatr Pathol Lab Med 1996; 16:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/68\">",
"      Huppertz B, Kadyrov M, Kingdom JC. Apoptosis and its role in the trophoblast. Am J Obstet Gynecol 2006; 195:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/69\">",
"      Cetin I, Foidart JM, Miozzo M, et al. Fetal growth restriction: a workshop report. Placenta 2004; 25:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/70\">",
"      Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the placenta and the origins of placental insufficiency. Semin Fetal Neonatal Med 2004; 9:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/71\">",
"      Kingdom J, Huppertz B, Seaward G, Kaufmann P. Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol 2000; 92:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/72\">",
"      Fox H. Pathology of the placenta. Clin Obstet Gynaecol 1986; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/73\">",
"      Rayburn W, Sander C, Compton A. Histologic examination of the placenta in the growth-retarded fetus. Am J Perinatol 1989; 6:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/74\">",
"      Rodriguez JG, Porter HJ, Andrews HS, Soothill PW. Placental lesions: is growth a predictor of bad outcome? Fetal Diagn Ther 1997; 12:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/75\">",
"      Salafia CM, Minior VK, Pezzullo JC, et al. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol 1995; 173:1049.",
"     </a>",
"    </li>",
"    <li>",
"     Fox, H. The pathology of the placenta. 2nd edition, WB Saunders, Philadelphia, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/77\">",
"      Naeye RL. Placental infarction leading to fetal or neonatal death. A prospective study. Obstet Gynecol 1977; 50:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/78\">",
"      Tettey Y, Wiredu EK. Autopsy studies on still births in Korle Bu Teaching Hospital: pathological findings in still births and their placentae. West Afr J Med 1997; 16:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/79\">",
"      Corr&ecirc;a RR, Gilio DB, Cavellani CL, et al. Placental morphometrical and histopathology changes in the different clinical presentations of hypertensive syndromes in pregnancy. Arch Gynecol Obstet 2008; 277:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/80\">",
"      Vinnars MT, Wijnaendts LC, Westgren M, et al. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008; 51:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/81\">",
"      Zhang P, Schmidt M, Cook L. Maternal vasculopathy and histologic diagnosis of preeclampsia: poor correlation of histologic changes and clinical manifestation. Am J Obstet Gynecol 2006; 194:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/82\">",
"      Rayne SC, Kraus FT. Placental thrombi and other vascular lesions. Classification, morphology, and clinical correlations. Pathol Res Pract 1993; 189:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/83\">",
"      Redline RW, Wilson-Costello D, Borawski E, et al. Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. Arch Pathol Lab Med 1998; 122:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/84\">",
"      Sander CM, Gilliland D, Flynn MA, Swart-Hills LA. Risk factors for recurrence of hemorrhagic endovasculitis of the placenta. Obstet Gynecol 1997; 89:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/85\">",
"      Sander CH, Stevens NG. Hemorrhagic endovasculitis of the placenta: an indepth morphologic appraisal with initial clinical and epidemiologic observations. Pathol Annu 1984; 19 Pt 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/86\">",
"      Sander CH, Kinnane L, Stevens NG. Hemorrhagic endovasculitis of the placenta: a clinicopathologic entity associated with adverse pregnancy outcome. Compr Ther 1985; 11:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/87\">",
"      Sander CH, Kinnane L, Stevens NG, Echt R. Haemorrhagic endovasculitis of the placenta: a review with clinical correlation. Placenta 1986; 7:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/88\">",
"      Redline RW, Pappin A. Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi. Hum Pathol 1995; 26:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/89\">",
"      Ogino S, Redline RW. Villous capillary lesions of the placenta: distinctions between chorangioma, chorangiomatosis, and chorangiosis. Hum Pathol 2000; 31:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/90\">",
"      Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/91\">",
"      Vern TZ, Alles AJ, Kowal-Vern A, et al. Frequency of factor V(Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 2000; 31:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/92\">",
"      Kraus FT. Placental thrombi and related problems. Semin Diagn Pathol 1993; 10:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/93\">",
"      Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol 1999; 30:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/94\">",
"      Batcup G, Tovey LA, Longster G. Fetomaternal blood group incompatibility studies in placental intervillous thrombosis. Placenta 1983; 4 Spec No:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/95\">",
"      Kaplan C, Blanc WA, Elias J. Identification of erythrocytes in intervillous thrombi: a study using immunoperoxidase identification of hemoglobins. Hum Pathol 1982; 13:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/96\">",
"      Hoogland HJ, de Haan J, Vooys GP. Ultrasonographic diagnosis of intervillous thrombosis related to Rh isoimmunization. Gynecol Obstet Invest 1979; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/97\">",
"      Rolschau J. Infarctions and intervillous thrombosis in placenta, and their association with intrauterine growth retardation. Acta Obstet Gynecol Scand Suppl 1978; 72:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/98\">",
"      Biankin SA, Arbuckle SM, Graf NS. Autopsy findings in a series of five cases of fetomaternal haemorrhages. Pathology 2003; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/99\">",
"      Khalifa MA, Gersell DJ, Hansen CH, Lage JM. Hepatic (hepatocellular) adenoma of the placenta: a study of four cases. Int J Gynecol Pathol 1998; 17:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/100\">",
"      Soma H, Watanabe Y, Hata T. Chorangiosis and chorangioma in three cohorts of placentas from Nepal, Tibet, and Japan. Reprod Fertil Dev 1995; 7:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/101\">",
"      Takayama M, Soma H, Yaguchi S, et al. Abnormally large placenta associated with Beckwith-Wiedemann syndrome. Gynecol Obstet Invest 1986; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/102\">",
"      Benirschke K. Recent trends in chorangiomas, especially those of multiple and recurrent chorangiomas. Pediatr Dev Pathol 1999; 2:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/103\">",
"      Chen CP, Chern SR, Wang TY, et al. Pregnancy with concomitant chorangioma and placental vascular malformation with mesenchymal hyperplasia. Hum Reprod 1997; 12:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/104\">",
"      Sabhikhi AK, Chaudhury MC, Singh D, Raja LN. Chorangioma of the placenta with hydrops fetalis. Indian Pediatr 1996; 33:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/105\">",
"      Majlessi HF, Wagner KM, Brooks JJ. Atypical cellular chorangioma of the placenta. Int J Gynecol Pathol 1983; 1:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/106\">",
"      Kohler HG, Iqbal N, Jenkins DM. Chorionic haemangiomata and abruptio placentae. Case report and review. Br J Obstet Gynaecol 1976; 83:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/107\">",
"      Jones CE, Rivers RP, Taghizadeh A. Disseminated intravascular coagulation and fetal hydrops in a newborn infant in association with a chorangioma of placenta. Pediatrics 1972; 50:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/108\">",
"      Kim CK, Benirschke K, Connolly KS. Chorangioma of the placenta. Chromosomal and electron microscopic studies. Obstet Gynecol 1971; 37:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/109\">",
"      Sepulveda W, Alcalde JL, Schnapp C, Bravo M. Perinatal outcome after prenatal diagnosis of placental chorioangioma. Obstet Gynecol 2003; 102:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/110\">",
"      Elag&ouml;z S, Aker H, Cetin A. Placental teratoma. A case report. Eur J Obstet Gynecol Reprod Biol 1998; 80:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/111\">",
"      Shimojo H, Itoh N, Shigematsu H, Yamazaki T. Mature teratoma of the placenta. Pathol Int 1996; 46:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/112\">",
"      Koumantakis E, Makrigiannakis A, Froudarakis G, et al. Teratoma of the placenta. A case report. Clin Exp Obstet Gynecol 1996; 23:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/113\">",
"      Wang L, Du X, Li M. Placental teratoma. A case report and review of the literature. Pathol Res Pract 1995; 191:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/114\">",
"      Jaswal, TS, Sen, R, Singh, S, et al. Teratoma of the placenta. J Indian Med Assoc 1995; 93:362,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/115\">",
"      Zanardini C, Papageorghiou A, Bhide A, Thilaganathan B. Giant placental chorioangioma: natural history and pregnancy outcome. Ultrasound Obstet Gynecol 2010; 35:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/116\">",
"      Eltorky M, Khare VK, Osborne P, Shanklin DR. Placental metastasis from maternal carcinoma. A report of three cases. J Reprod Med 1995; 40:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/117\">",
"      Baergen RN, Johnson D, Moore T, Benirschke K. Maternal melanoma metastatic to the placenta: a case report and review of the literature. Arch Pathol Lab Med 1997; 121:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/118\">",
"      Wang T, Hamann W, Hartge R. Structural aspects of a placenta from a case of maternal acute lymphatic leukaemia. Placenta 1983; 4:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/119\">",
"      Russell P, Laverty CR. Malignant melanoma metastases in the placenta: a case report. Pathology 1977; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/120\">",
"      Sokol RJ, Hutchison P, Cowan D, Reed GB. Amelanotic melanoma metastatic to the placenta. Am J Obstet Gynecol 1976; 124:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/121\">",
"      Potter JF, Schoeneman M. Metastasis of maternal cancer to the placenta and fetus. Cancer 1970; 25:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/122\">",
"      Tsukamoto N, Kashimura Y, Sano M, et al. Choriocarcinoma occurring within the normal placenta with breast metastasis. Gynecol Oncol 1981; 11:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/123\">",
"      Choriocarcinoma of the placenta. By the OSMA Committee on Maternal Health. Ohio State Med J 1975; 71:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/124\">",
"      Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003; 21:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/125\">",
"      Altman JF, Lowe L, Redman B, et al. Placental metastasis of maternal melanoma. J Am Acad Dermatol 2003; 49:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/126\">",
"      Pavlidis N. Lung cancer during pregnancy: an emerging issue. Lung Cancer 2008; 59:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/127\">",
"      Sebire NJ, Jauniaux E. Fetal and placental malignancies: prenatal diagnosis and management. Ultrasound Obstet Gynecol 2009; 33:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/128\">",
"      Anders D, Kindermann G, Pfeifer U. Metastasizing fetal neuroblastoma with involvement of the placenta simulating fetal erythroblastosis. Report of two cases. J Pediatr 1973; 82:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/129\">",
"      Sotelo-Avila C, Graham M, Hanby DE, Rudolph AJ. Nevus cell aggregates in the placenta. A histochemical and electron microscopic study. Am J Clin Pathol 1988; 89:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/130\">",
"      Higgins M, McAuliffe FM, Mooney EE. Clinical associations with a placental diagnosis of delayed villous maturation: a retrospective study. Pediatr Dev Pathol 2011; 14:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/131\">",
"      Altshuler G. Chorangiosis. An important placental sign of neonatal morbidity and mortality. Arch Pathol Lab Med 1984; 108:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/132\">",
"      Benirschke K. Placenta pathology questions to the perinatologist. J Perinatol 1994; 14:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/133\">",
"      Benirschke K. Obstetrically important lesions of the umbilical cord. J Reprod Med 1994; 39:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/134\">",
"      Bendon RW, Hommel AB. Maternal floor infarction in autoimmune disease: two cases. Pediatr Pathol Lab Med 1996; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/135\">",
"      Mandsager NT, Bendon R, Mostello D, et al. Maternal floor infarction of the placenta: prenatal diagnosis and clinical significance. Obstet Gynecol 1994; 83:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/136\">",
"      Nickel RE. Maternal floor infarction: an unusual cause of intrauterine growth retardation. Am J Dis Child 1988; 142:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/137\">",
"      Naeye RL. Maternal floor infarction. Hum Pathol 1985; 16:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/138\">",
"      Clewell WH, Manchester DK. Recurrent maternal floor infarction: a preventable cause of fetal death. Am J Obstet Gynecol 1983; 147:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/139\">",
"      Doss BJ, Greene MF, Hill J, et al. Massive chronic intervillositis associated with recurrent abortions. Hum Pathol 1995; 26:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/140\">",
"      Jacques SM, Qureshi F. Chronic intervillositis of the placenta. Arch Pathol Lab Med 1993; 117:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/141\">",
"      Fuke Y, Aono T, Imai S, et al. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecol Obstet Invest 1994; 38:5.",
"     </a>",
"    </li>",
"    <li>",
"     Benirschke, K. and Kaufman, P. The pathology of the human placenta. 3rd ed. 1995, New York: Springer-Verlag.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/143\">",
"      Khong TY. From delivery suite to laboratory: optimizing returns from placental examination in medico-legal defence. Aust N Z J Obstet Gynaecol 1997; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/144\">",
"      Altshuler G. Placenta within the medicolegal imperative. Arch Pathol Lab Med 1991; 115:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/145\">",
"      Benirschke K. The placenta in the litigation process. Am J Obstet Gynecol 1990; 162:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/146\">",
"      Hua M, Odibo AO, Macones GA, et al. Single umbilical artery and its associated findings. Obstet Gynecol 2010; 115:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/147\">",
"      Thummala MR, Raju TN, Langenberg P. Isolated single umbilical artery anomaly and the risk for congenital malformations: a meta-analysis. J Pediatr Surg 1998; 33:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/148\">",
"      Dagklis T, Defigueiredo D, Staboulidou I, et al. Isolated single umbilical artery and fetal karyotype. Ultrasound Obstet Gynecol 2010; 36:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/149\">",
"      Predanic M, Perni SC, Friedman A, et al. Fetal growth assessment and neonatal birth weight in fetuses with an isolated single umbilical artery. Obstet Gynecol 2005; 105:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/150\">",
"      Catanzarite VA, Hendricks SK, Maida C, et al. Prenatal diagnosis of the two-vessel cord: implications for patient counselling and obstetric management. Ultrasound Obstet Gynecol 1995; 5:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/151\">",
"      Wiegand S, McKenna DS, Croom C, et al. Serial sonographic growth assessment in pregnancies complicated by an isolated single umbilical artery. Am J Perinatol 2008; 25:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/152\">",
"      Sep&uacute;lveda WH. Antenatal sonographic detection of single umbilical artery. J Perinat Med 1991; 19:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/153\">",
"      Murphy-Kaulbeck L, Dodds L, Joseph KS, Van den Hof M. Single umbilical artery risk factors and pregnancy outcomes. Obstet Gynecol 2010; 116:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/154\">",
"      Van den Hof MC, Wilson RD, Diagnostic Imaging Committee, Society of Obstetricians and Gynaecologists of Canada, Genetics Committee, Society of Obstetricians and Gynaecologists of Canada. Fetal soft markers in obstetric ultrasound. J Obstet Gynaecol Can 2005; 27:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/155\">",
"      Lubusky M, Dhaifalah I, Prochazka M, et al. Single umbilical artery and its siding in the second trimester of pregnancy: relation to chromosomal defects. Prenat Diagn 2007; 27:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/156\">",
"      Sherer DM, Anyaegbunam A. Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part II. Obstet Gynecol Surv 1997; 52:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/157\">",
"      Sherer DM, Anyaegbunam A. Prenatal ultrasonographic morphologic assessment of the umbilical cord: a review. Part I. Obstet Gynecol Surv 1997; 52:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/158\">",
"      Parilla BV, Tamura RK, MacGregor SN, et al. The clinical significance of a single umbilical artery as an isolated finding on prenatal ultrasound. Obstet Gynecol 1995; 85:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/159\">",
"      Clausen I. Umbilical cord anomalies and antenatal fetal deaths. Obstet Gynecol Surv 1989; 44:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/160\">",
"      Heifetz SA. Single umbilical artery. A statistical analysis of 237 autopsy cases and review of the literature. Perspect Pediatr Pathol 1984; 8:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/161\">",
"      DeFigueiredo D, Dagklis T, Zidere V, et al. Isolated single umbilical artery: need for specialist fetal echocardiography? Ultrasound Obstet Gynecol 2010; 36:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/162\">",
"      Gossett DR, Lantz ME, Chisholm CA. Antenatal diagnosis of single umbilical artery: is fetal echocardiography warranted?. Obstet Gynecol 2002; 100:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/163\">",
"      Khong TY, George K. Chromosomal abnormalities associated with a single umbilical artery. Prenat Diagn 1992; 12:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/164\">",
"      Nyberg DA, Mahony BS, Luthy D, Kapur R. Single umbilical artery. Prenatal detection of concurrent anomalies. J Ultrasound Med 1991; 10:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/165\">",
"      Abuhamad AZ, Shaffer W, Mari G, et al. Single umbilical artery: does it matter which artery is missing? Am J Obstet Gynecol 1995; 173:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/166\">",
"      Chetty-John S, Zhang J, Chen Z, et al. Long-term physical and neurologic development in newborn infants with isolated single umbilical artery. Am J Obstet Gynecol 2010; 203:368.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/167\">",
"      Sander CH. Hemorrhagic endovasculitis and hemorrhagic villitis of the placenta. Arch Pathol Lab Med 1980; 104:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/168\">",
"      Sander CM. Update: etiology, diagnosis and management of hemorrhagic endovasculitis of the placenta. Compr Ther 1991; 17:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/169\">",
"      Salafia CM, Vintzileos AM, Silberman L, et al. Placental pathology of idiopathic intrauterine growth retardation at term. Am J Perinatol 1992; 9:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/170\">",
"      Anderson GM, Jacobs-Stannard A, Chawarska K, et al. Placental trophoblast inclusions in autism spectrum disorder. Biol Psychiatry 2007; 61:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/171\">",
"      Lage JM, Roberts DJ. Choriocarcinoma in a term placenta: pathologic diagnosis of tumor in an asymptomatic patient with metastatic disease. Int J Gynecol Pathol 1993; 12:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/172\">",
"      Roberts DJ, Mutter GL. Advances in the molecular biology of gestational trophoblastic disease. J Reprod Med 1994; 39:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/173\">",
"      Goldenberg RL, Andrews WW, Faye-Petersen O, et al. The Alabama Preterm Birth Project: placental histology in recurrent spontaneous and indicated preterm birth. Am J Obstet Gynecol 2006; 195:792.",
"     </a>",
"    </li>",
"    <li>",
"     Baldwin, V. Pathology of Multiple Gestation. 1994; New York: Springer-Verlag.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/175\">",
"      Souter VL, Kapur RP, Nyholt DR, et al. A report of dizygous monochorionic twins. N Engl J Med 2003; 349:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/176\">",
"      Yoon G, Beischel LS, Johnson JP, Jones MC. Dizygotic twin pregnancy conceived with assisted reproductive technology associated with chromosomal anomaly, imprinting disorder, and monochorionic placentation. J Pediatr 2005; 146:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/46/27370/abstract/177\">",
"      Phung DT, Blickstein I, Goldman RD, et al. The Northwestern Twin Chorionicity Study: I. Discordant inflammatory findings that are related to chorionicity in presenting versus nonpresenting twins. Am J Obstet Gynecol 2002; 186:1041.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2282 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-BCE9E00093-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27370=[""].join("\n");
var outline_f26_46_27370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UMBILICAL CORD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Congenital remnants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Meconium stained cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arterial and venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Amniotic fluid contaminants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Meconium stained membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Maternal vascular and hypertensive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fetal disorders affecting the membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hemosiderin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vernix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PARENCHYMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Villitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acute villitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lympho-histiocytic (\"chronic\") villitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ischemic lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Placental \"underperfusion\"",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fetal vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Masses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Intervillous thrombi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Chorioangioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Metastatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36807005\">",
"      - Villous maturational arrest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3685445\">",
"      - Chorangiosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3685272\">",
"      - Maternal floor infarct and massive chronic intervillositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Maternal floor infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Massive chorionic intervillositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Abruptio placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SELECTED PLACENTAL FINDINGS AND DIAGNOSES OF PERINATAL AND MEDICOLEGAL IMPORTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Acute versus chronic stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Single umbilical artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Disorders affecting the fetus and newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Maternal diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Recurrent preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/2282\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/2282|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/33/7704\" title=\"picture 1\">",
"      Funisitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/18/13604\" title=\"picture 2\">",
"      Candida placentitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/32/26117\" title=\"picture 3\">",
"      Meconium myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/22/38255\" title=\"picture 4\">",
"      Hematoma umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/16/33025\" title=\"picture 5\">",
"      Microscopy cord hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/34/43558\" title=\"picture 6\">",
"      Severe acute chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/62/10212\" title=\"picture 7\">",
"      Meconium stained membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/45/34515\" title=\"picture 8\">",
"      Amnion nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/52/37705\" title=\"picture 9\">",
"      Acute villitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/50/42793\" title=\"picture 10\">",
"      Chronic villitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/62/37865\" title=\"picture 11\">",
"      Chronic placenta underperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/19/32056\" title=\"picture 12\">",
"      Hemorrhagic endovasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/34/2597\" title=\"picture 13\">",
"      Laminated intervillous thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/22/37225\" title=\"picture 14\">",
"      Chorioangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/0/2056\" title=\"picture 15\">",
"      Terminal villi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/30/30184\" title=\"picture 16\">",
"      Villous maturational arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/17/15637\" title=\"picture 17\">",
"      Maternal floor infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/62/36841\" title=\"picture 18\">",
"      Massive chronic intervillositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/2282|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/12/7374\" title=\"table 1\">",
"      Placental weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21929?source=related_link\">",
"      Placental pathology in cases of neurologically impaired infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_46_27371="Trials of MAC therapy in AIDS";
var content_f26_46_27371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trials of MAC therapy in patients with AIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Trial",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatments",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Curavium ANRS 033*",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        CLA + ETH + RBT superior to CLA + CLO",
"       </td>",
"       <td>",
"        Prevention of relapse and resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CCTG 549&bull;",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        CLA + EMB + CLO superior to CLA + CLO",
"       </td>",
"       <td>",
"        Relapse and resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canadian Trials Network&Delta;",
"       </td>",
"       <td>",
"        229",
"       </td>",
"       <td>",
"        CLA + EMB + RBT superior to Cipro + RIF + EMB + CLO",
"       </td>",
"       <td>",
"        Survival, reduced bacteremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abbott&loz;",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        CLA + EMB superior to CLA + CLO + EMB",
"       </td>",
"       <td>",
"        Survival",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CLA: clarithromycin; ETH: ethambutol; RBT: rifabutin; CLO: clofazimine; Cipro: ciprofloxacin; RIF: rifampin.",
"    </div>",
"    <div class=\"reference\">",
"     * May, T, Brel, F, Beuscart, C, et al. Clin Infect Dis 1997; 25:621.",
"     <br>",
"      &bull; Dube, MP, Sattler, FR, Torriani, FJ, et al. J Infect Dis 1997; 176:1225.",
"      <br>",
"       &Delta; Shafran, SD, Singer, J, Zarowny, DP, et al. N Engl J Med 1996; 335:377.",
"       <br>",
"        &loz; Chaisson, RE, Keiser, P, Pierce, M, et al. AIDS 1997; 11:311.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27371=[""].join("\n");
var outline_f26_46_27371=null;
var title_f26_46_27372="Independent insomnia PI";
var content_f26_46_27372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Independent insomnia disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Insomnia is called an \"independent disorder\" if it is not caused by an underlying problem, such as an illness. The following are insomnia disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Inadequate sleep hygiene",
"        </strong>",
"        - Insomnia may also be related to poor sleep hygiene. Poor sleep hygiene refers to habits that interfere with a person's ability to fall asleep and stay asleep. Examples include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Irregular sleep schedule (daytime naps, irregular sleep or wake times, excessive time in bed)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Use of substances before bedtime that disturb sleep (caffeine, alcohol, and tobacco)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Mentally or physically stimulating activity before bedtime (eg, exercise)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Use of bedroom for non-sleep activities (studying, snacking)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Uncomfortable sleep environment (too loud, hot/cold, bright)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Psychophysiological insomnia",
"        </strong>",
"        - People with psychophysiological insomnia have a chronic insomnia problem related to anxiety and increased tension at bedtime. The person does not have phobias, anxiety disorders, or other mental health problems, but they do feel very anxious and concerned about their sleep problems. Eventually the person may become excessively worried, fearful, and frustrated with not being able to sleep that he or she develops habits and responses that make getting to sleep and staying asleep very difficult.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Idiopathic insomnia",
"        </strong>",
"        - People with idiopathic insomnia have had trouble falling or staying asleep their entire lives, often starting in childhood. This may cause difficulty in functioning during the day. Experts think it may be linked to genetically determined abnormalities in the sleep-promoting or arousal systems. People with idiopathic insomnia often have family members with the condition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Behavioral insomnia of childhood",
"        </strong>",
"        - Behavioral insomnia of childhood describes a child who requires specific circumstances, such as a parent or favorite toy, to fall asleep. This usually occurs because child has become accustomed to having the parent/toy over time. Not having the required object can make it difficult for the child to fall asleep or return to sleep during the night. Between 10 and 30 percent of children may have this problem, beginning at six months of age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paradoxical insomnia",
"        </strong>",
"        - In some cases, people complain of insomnia or sleeplessness although sleep tests show a normal sleep pattern. This is called paradoxical insomnia or sleep state misperception.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27372=[""].join("\n");
var outline_f26_46_27372=null;
var title_f26_46_27373="Drivers with CHD";
var content_f26_46_27373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with known CHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physiologic/functional",
"       </td>",
"       <td class=\"subtitle1\">",
"        Certification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Re-certification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Post MI",
"       </td>",
"       <td rowspan=\"12\">",
"        <p>",
"         Risk of recurrent major cardiac event highest within the first months post-MI",
"        </p>",
"        <p>",
"         Drivers in a rehabilitation program can receive comprehensive secondary prevention therapy",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        No if:",
"       </td>",
"       <td rowspan=\"6\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Recurrent angina symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Post-MI ejection fraction &lt;40 percent (by echocardiogram or ventriculogram)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Abnormal ETT demonstrated prior to planned work return",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ischemic changes on rest ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Poor tolerance to current cardiovascular medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Biennial ETT at minimum (if test positive or inconclusive, imaging stress test may be indicated)",
"        </p>",
"        <p>",
"         Cardiologist examination recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - At least 2 months post-MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Cleared by cardiologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - No angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Post-MI ejection fraction &ge;40 percent (by echocardiogram or ventriculogram)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Tolerance to current cardiovascular medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Angina pectoris",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Lower end of spectrum among CHD patients for risk of adverse clinical outcomes",
"        </p>",
"        <p>",
"         Condition usually implies at least one coronary artery has hemodynamically significant narrowing",
"        </p>",
"       </td>",
"       <td>",
"        Yes, if asymptomatic",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        No if:",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Biennial ETT at minimum (if test positive or inconclusive, imaging stress test may be indicated)",
"        </p>",
"        <p>",
"         Cardiologist examination recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Rest angina or change in angina pattern within 3 months of examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Abnormal ETT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ischemic changes on rest ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Intolerance to cardiovascular therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        Post PCI",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         Rapid recovery for elective PCIs for stable angina",
"        </p>",
"        <p>",
"         Delayed re-stenosis is the major PCI limitation and requires intensive secondary prevention",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Recommend Cardiologist examination",
"        </p>",
"        <p>",
"         Biennial ETT (if test positive or inconclusive, imaging stress test may be indicated)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - At least 1 week after procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Cardiologist's approval and tolerance to medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - ETT 3 to 6 months after PCI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        No if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Incomplete healing or complication at vascular access site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Rest angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ischemic ECG changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Post Coronary Artery Bypass Surgery (CABG)",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Delay in return to work to allow sternal incision healing",
"        </p>",
"        <p>",
"         Because of increasing risk of graft closure over time, ETT is obtained",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         After 5 years: Annual ETT",
"        </p>",
"        <p>",
"         Imaging stress test may be indicated",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - At least 3 months after CABG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - LVEF &ge;40 percent post CABG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Approval by cardiologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Asymptomatic and tolerance to medications",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal, R, Braunstein, J, Connolly, H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27373=[""].join("\n");
var outline_f26_46_27373=null;
var title_f26_46_27374="AED pharmacologic properties";
var content_f26_46_27374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic properties of antiepileptic drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolism and clearance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enzyme induction/inhibition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein binding, percent*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half life in adults (hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        <p>",
"         &gt;90 percent metabolized by CYP 3A4 and 2C8 (minor) to active (epoxide) and inactive metabolites",
"        </p>",
"        <p>",
"         Dose adjustment is needed in severe renal or hepatic insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Potent and broad spectrum inducer of CYP and P-gp",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        <p>",
"         25-65 (initial use, enzyme inducing naive patient)",
"        </p>",
"        <p>",
"         8-22 (after several weeks due to auto induction)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethosuximide",
"       </td>",
"       <td>",
"        ~80 percent metabolized by CYP 3A4 and non-CYP transformations to inactive metabolites",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        40-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felbamate",
"       </td>",
"       <td>",
"        <p>",
"         60 percent metabolized by CYP 3A4 and 2E1 (minor); ~30 percent renally excreted as unchanged drug",
"        </p>",
"        <p>",
"         Dose adjustment is needed in renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Induces CYP 3A4 (moderate)",
"        </p>",
"        <p>",
"         Inhibits CYP 2C19 (minor)",
"        </p>",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        13-22 (prolonged in renal insufficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        <p>",
"         &gt;95 percent renally excreted as unchanged drug (does not undergo metabolism)",
"        </p>",
"        <p>",
"         Dose adjustment is needed in renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        5-7 (prolonged in renal insufficiency; &gt;130 hours in anuria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacosamide",
"       </td>",
"       <td>",
"        <p>",
"         &gt;40 percent renally excreted as unchanged drug; 30 percent metabolized by non-CYP transformations (including methylation) to inactive metabolite",
"        </p>",
"        <p>",
"         Dose adjustment is needed in renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Inhibits 2C19 (minor)",
"       </td>",
"       <td>",
"        &lt;15",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        <p>",
"         &gt;90 percent metabolized by non-CYP transformations (including glucuronidation) to inactive metabolites",
"        </p>",
"        <p>",
"         Dose adjustment is needed in moderate to severe renal or hepatic insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        May induce its own metabolism by glucuronidation (minor)",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        12-62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levetiracetam",
"       </td>",
"       <td>",
"        <p>",
"         &gt;65 renally excreted as unchanged drug; 24 percent metabolized by non-CYP transformation (including hydrolysis) to inactive metabolites",
"        </p>",
"        <p>",
"         Dose adjustment is needed in renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td>",
"        6-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        <p>",
"         Prodrug. &gt;90 percent metabolized by non-CYP transformations to pharmacologically active and inactive metabolites",
"        </p>",
"        <p>",
"         Dose adjustment is needed in severe renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Induces CYP 3A4",
"        <span style=\"color: #ff0000;\">",
"        </span>",
"        (moderate to severe) and glucuronidation but does not induce its own metabolism",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        9 (active metabolite, prolonged in renal insufficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perampanel&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         &gt;90 percent metabolized by CYP 3A4, 3A5 and non-CYP transformations to inactive metabolites",
"        </p>",
"        <p>",
"         Dose adjustment is needed in mild or moderate hepatic insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Appears to induce metabolism of progestin- containing hormonal contraceptives",
"       </td>",
"       <td>",
"        95&nbsp;",
"       </td>",
"       <td>",
"        105&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital",
"       </td>",
"       <td>",
"        <p>",
"         75 percent metabolized by CYP 2C19, 2C9 (minor) and 2E1 (minor) to inactive metabolites; 25 percent excreted renally as unchanged drug",
"        </p>",
"        <p>",
"         Dose adjustment is needed in severe renal or hepatic insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Potent and broad spectrum inducer of CYP and glucuronidation",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        75-110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        <p>",
"         &gt;90 percent metabolized by CYP 2C9, 2C19 and 3A4 (minor) and non-CYP transformations to inactive metabolites; clearance is dose dependent, saturable, and may be subject to genetic polymorphism",
"        </p>",
"        <p>",
"         Dose adjustment is needed in severe renal or hepatic insufficiency; monitoring of free (unbound) concentrations also suggested",
"        </p>",
"       </td>",
"       <td>",
"        Potent and broad spectrum inducer of CYP and glucuronidation",
"       </td>",
"       <td>",
"        90-95",
"       </td>",
"       <td>",
"        9- &gt;42 (dose dependent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregabalin",
"       </td>",
"       <td>",
"        <p>",
"         &gt;95 excreted renally as unchanged drug",
"        </p>",
"        <p>",
"         Dose adjustment is needed in renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primidone",
"       </td>",
"       <td>",
"        <p>",
"         75 percent metabolized by CYP 2C19, 2C9 (minor) and 2E1 (minor) to active intermediates; ~25 percent excreted renally as unchanged drug",
"        </p>",
"        <p>",
"         Dose adjustment is needed in moderate and severe renal or hepatic insufficiency; close monitoring of plasma levels suggested",
"        </p>",
"       </td>",
"       <td>",
"        Potent and broad spectrum inducer of CYP",
"       </td>",
"       <td>",
"        0-20",
"       </td>",
"       <td>",
"        <p>",
"         10-15 (parent)",
"        </p>",
"        <p>",
"         29-100 (active metabolite)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rufinamide",
"       </td>",
"       <td>",
"        &gt;90 percent metabolized by non-CYP transformations to inactive metabolites",
"       </td>",
"       <td>",
"        <p>",
"         Induces CYP 3A4 (minor)",
"        </p>",
"        <p>",
"         Inhibits CYP 2E1 (minor)",
"        </p>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        6-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiagabine",
"       </td>",
"       <td>",
"        &gt;90 percent metabolized by CYP 3A4 and non-CYP transformations to inactive metabolites",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        <p>",
"         7-9",
"        </p>",
"        <p>",
"         2-5 (with enzyme-inducing AEDs)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topiramate",
"       </td>",
"       <td>",
"        <p>",
"         &gt;65 percent excreted renally as unchanged drug; &lt;30 percent metabolized by non-CYP transformations to inactive metabolites; extent of metabolism is increased ~50 percent in patients receiving enzyme inducing AEDs",
"        </p>",
"        <p>",
"         Dose adjustment is needed in moderate and severe renal or hepatic insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits 2C19 (minor)",
"        </p>",
"        <p>",
"         Induces CYP 3A4 (minor)",
"        </p>",
"       </td>",
"       <td>",
"        9-17",
"       </td>",
"       <td>",
"        12-24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"       <td>",
"        <p>",
"         &gt;95 percent undergoes complex transformations including CYP 2C9, 2C19, 2A6, glucuronidation and non-CYP metabolism",
"        </p>",
"        <p>",
"         Dose adjustment is needed in hepatic insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate broad spectrum inhibitor including CYP 2A6, 2B6, 2C9, 2C19, 2E1 and glucuronidation",
"        </p>",
"        <p>",
"         Minor or moderate inducer of CYP 2A6",
"        </p>",
"       </td>",
"       <td>",
"        80-95",
"       </td>",
"       <td>",
"        7-16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigabatrin",
"       </td>",
"       <td>",
"        <p>",
"         &gt;70 percent excreted renally as unchanged drug",
"        </p>",
"        <p>",
"         Dose adjustment is needed in renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Induces CYP 2C9",
"       </td>",
"       <td>",
"        0&nbsp;",
"       </td>",
"       <td>",
"        5-13 (unrelated to duration of action)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonisamide",
"       </td>",
"       <td>",
"        <p>",
"         &gt;70 percent metabolized by CYP 3A4, 2C19 (minor) and non-CYP transformations",
"        </p>",
"        <p>",
"         Dose adjustment and/or slower titration is needed in mild renal insufficiency or hepatic insufficiency; not recommended in patients with moderate or severe renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    AEDs: antiepileptic drugs; CYP: cytochrome P450; P-gp: membrane P-glycoprotein multidrug resistance transporter",
"    <div class=\"footnotes\">",
"     * Highly protein-bound AEDs exhibit altered pharmacokinetics, including greater therapeutic and toxic effects and drug interactions, when given in usual doses to patients with low serum albumin or protein binding affinity (eg, due to nephrotic syndrome or acidosis).&nbsp; Dose alteration is needed and monitoring of unbound (free) AED serum concentrations is suggested. See UpToDate topic for additional information.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bazil CW. Antiepileptic drugs in the 21st century. CNS Spectr 2001; 6:756.",
"      </li>",
"      <li>",
"       Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67:S28.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27374=[""].join("\n");
var outline_f26_46_27374=null;
var title_f26_46_27375="Manual testing grip strength";
var content_f26_46_27375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manual testing of grip strength",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Manual gripping of the examiner's fingers provides a crude estimate of grip strength.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_46_27375=[""].join("\n");
var outline_f26_46_27375=null;
